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Identifying Demographic, Clinical, And Geographic Features Of Cervical Cancer
Patients Presenting To A Multidisciplinary Team (mdt) Clinic In Gaborone,
Botswana
Abstract
In Botswana, cervical cancer is the most common cancer and leading cause of cancer death for females.
The capital, Gaborone, houses the only gynecological cancer multi-disciplinary team (MDT) clinic in the
country with the expertise and facilities able to provide standard of care for cervical cancer patients.
Botswana, with a 20% prevalence of human immunodeficiency virus (HIV), is experiencing increasing
morbidity and mortality from HIV/AIDS-related cancers, including cervical cancer). Data, resources, and
interventions are needed to combat this growing cancer burden. For this dissertation, we abstracted
social, biological, clinical, and geographic characteristics of cervical cancer patients presenting for
treatment. First, we used logistic regression to investigate individual patient characteristics associated
with tumor stage at presentation. We found the odds of having late-stage cervical cancer at presentation
decreased with previous cervical cancer screening, whereas experiencing abnormal vaginal bleeding and
never being married were associated with increased odds of late-stage cervical cancer. Second, we used
geo-spatial methods to detect areas with high or low clustering of cervical cancer cases to identify subdistricts with disproportionate access to the MDT clinic. We identified five sub-districts with clustering,
specifically highlighting sub-districts with disproportionately lower rates of cervical cancer cases
presenting for care. Furthermore, we noted individual level predictors (HIV status and presence of
abnormal vaginal bleeding) among patients living in areas with disproportionate rates. Third, we used
multinomial logistic regression to study travel time from a patient’s residence to the MDT clinic and tumor
stage at presentation. We found that increased travel time was associated with later stages of cervical
cancer at presentation. Additionally, women with increased travel time to the MDT clinic were more likely
to be living with HIV, suggesting HIV status may influence referral to and receipt of cervical cancer care. In
conclusion, identifying individual, community, and geographic factors associated with late-stage
diagnosis and areas with low access to comprehensive cervical cancer care can guide future studies and
national health programs in developing strategies that target under-served areas with interventions to
improve early detection of cervical cancer. These strategies will be key in controlling the emerging
cervical cancer burden in Botswana.
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ABSTRACT

IDENTIFYING DEMOGRAPHIC, CLINICAL, AND GEOGRAPHIC FEATURES OF
CERVICAL CANCER PATIENTS PRESENTING TO A MULTIDISCIPLINARY TEAM
(MDT) CLINIC IN GABORONE, BOTSWANA

Tara Marie Friebel-Klingner
Anne Marie McCarthy

In Botswana, cervical cancer is the most common cancer and leading cause of cancer
death for females. The capital, Gaborone, houses the only gynecological cancer multidisciplinary team (MDT) clinic in the country with the expertise and facilities able to
provide standard of care for cervical cancer patients. Botswana, with a 20% prevalence
of human immunodeficiency virus (HIV), is experiencing increasing morbidity and
mortality from HIV/AIDS-related cancers, including cervical cancer. Data, resources, and
interventions are urgently needed to combat this growing burden. For this dissertation,
we abstracted social, biological, clinical, and geographic characteristics of cervical
cancer patients presenting for treatment to the MDT clinic. First, we used logistic
regression to investigate individual patient characteristics associated with tumor stage at
presentation. We found the odds of having late-stage cervical cancer at presentation
decreased with previous cervical cancer screening, whereas experiencing abnormal
vaginal bleeding and never being married were associated with an increased odds latestage cervical cancer. Second, we used geo-spatial analytical methods to detect areas
with high or low clustering of cervical cancer cases presenting for care in order to identify
vi

sub-districts with disproportionate access to the MDT clinic. We identified five subdistricts with clustering, specifically highlighting sub-districts with disproportionately lower
presentation rates of cervical cancer cases indicating poor access to comprehensive
cervical cancer care. Furthermore, we noted individual level predictors (HIV status and
presence of abnormal vaginal bleeding) among patients living in areas with
disproportionate rates. Third, we used multinomial logistic regression to study the travel
time from a patient’s village of residence to the MDT clinic and tumor stage. We found
that increased travel time was associated with later stages of cervical cancer at
presentation. Additionally, women with increased travel time to the MDT clinic were more
likely to be living with HIV, suggesting HIV status may also influencing referral to and
receipt of cervical cancer care for women living further from the clinic in Gaborone. In
conclusion, identifying individual, community, and geographic factors associated with
late-stage diagnosis provides valuable insight to guide future studies, interventions,
national health policy, and programs for developing strategies targeting under-served
areas and high-risk women to improve the early detection of cervical cancer, decrease
morbidity, and improve access to cancer treatment. These strategies will be key in
controlling the emerging cervical cancer burden in Botswana.
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CHAPTER 1. Introduction
The World Health Organization estimates that there were 570,000 cervical cancer cases
and 311,000 cervical cancer deaths in 2018, with more than 80% of the cervical cancer
deaths worldwide occurring in low-to-middle-income countries (LMICs), predominantly in
sub-Saharan Africa (SSA). In Botswana, cervical cancer is the most commonly
diagnosed cancer in women and the leading cause of cancer death. In LMICs, as the
chronic disease burden for diseases like cancer is accumulating, data, resources, and
interventions needed to address this growing concern. It is an opportune time in LMICs
to prioritize cancer care with the intent of reducing the impact of this disease.

Despite Botswana’s national healthcare system and cervical cancer screening program,
many cervical cancers are diagnosed at late stages (stage III or IV) and the mortality
rate is high. A partnership between the University of Botswana and University of
Pennsylvania (BUP), formed in 2001 to combat HIV/AIDs, has recognized the need to
expand priorities to include chronic diseases and has developed an infrastructure to
capture demographic, social and biological characteristics of cervical cancer patients
throughout Botswana, known as the Botswana cancer cohort. Botswana has a
population of approximately 2.3 million people and has government funded healthcare,
ensuring affordable healthcare for all citizens. The de-centralized health care system
ranges from health posts to referral hospitals. Health posts are staffed with a health
education assistant, a lay counselor, a nurse and occasionally a midwife or a doctor;
clinics offer mainly primary health care and outpatient services, including offering various
modes of screening or testing for cervical cancer. Hospitals are three tiers: district,
primary or referral hospitals. The most equipped facilities are referral hospitals, of which
1

there are 3 in the country. Referral hospitals are highly advanced facilities prepared to
deal with specialized diseases. Two of the referral hospitals are located in the capital,
Gaborone: Princess Marina Hospital (PMH) and Gaborone Private Hospital (GPH), and
one is in Francistown: Nyangabgwe Referral Hospital (NRH). With two of the country’s
referral hospitals in the capital city of Gaborone, the first multidisciplinary tumor clinic
(MDT) was formed in 2015 at PMH to provide comprehensive care for all gynecological
oncology patients in Botswana. The MDT clinic coordinates comprehensive
gynecological cancer care and has a highly specialized team, including the only
gynecological oncologist in the country and treats patients, as appropriate, with the only
radiation oncology facility located at GPH which sees and treats patients diagnosed with
cervical cancer referred from health facilities around Botswana.

This dissertation research provides a rich, detailed description of individual level social
and clinical characteristics as well as geographical associations of cervical cancers
presenting for staging and care at the MDT clinic in Botswana. Additionally, geographic
information systems (GIS) and spatial analysis, powerful epidemiologic tools for
understanding variability in health patterns, were used to identify areas in need of public
health interventions. This approach could particularly benefit Botswana, a country
characterized by a large geographic area and a dispersed population limited to one
cervical cancer treatment facility for the entire country.

The conceptual model for this work is presented in Figure 1.1. For this work we used the
cohort of patients presenting to the MDT clinic for staging and care. We first
investigated individual factors that differed according to tumor stage at presentation of
cervical cancer. Second, we identified geography and clustering of cervical cancer
2

cases throughout the country using spatial statistical methods. Lastly, we determined
how travel time from a patient’s residence relates to stage at presentation of cervical
cancer and identified factors impacting potential delays in accessing cancer care.

This research aims to highlight the growing cervical cancer burden in Botswana and
learn pertinent information that will lay a foundation for future studies to confirm and
characterize factors associated with the increasing burden of cervical cancer. This work
will contribute to the sparse literature regarding cervical cancer in this low resource
settings. We have identified important individual, community level, and health care level
and geographic factors that influence late stage of cervical cancer at presentation,
influencing delays and access to comprehensive cervical cancer care. These findings
will guide future studies and national health programs developing strategies that target
underserved areas with interventions to improve early detection of cervical cancer, to
ultimately improve survival for cervical cancer patients in Botswana.

1.2. Ethics approval
All work for this dissertation was approved under the parent study, “Treatment and
Outcomes of Patients Presenting with Cancer in Botswana,” \ by the University of
Pennsylvania as part of the Botswana-University of Pennsylvania Partnership (IRB:
820159 IRB#7 Penn) and by the Ministry of Health and Wellness of the Republic of
Botswana (HPDME 13/18/1).
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Figure 1. 1. Conceptual Model
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CHAPTER 2. Clinical and sociodemographic factors associated with late stage cervical
cancer diagnosis in Botswana

2.1. Abstract

2.1.1. Background

Cervical cancer is the leading cause of female cancer mortality in Botswana with the
majority of cervical cancer patients presenting with late-stage disease. The identification
of factors associated with late-stage disease could reduce the cervical cancer burden.
This study aims to identify potential patient level clinical and sociodemographic factors
associated with a late-stage diagnosis of cervical cancer in Botswana in order to help
inform future interventions at the community and individual levels to decrease cervical
cancer morbidity and mortality.

2.1.2. Methods

Women diagnosed with cervical cancer from January 2015 to March 2020 at two tertiary
hospitals in Gaborone, Botswana were included. The association between late-stage
(stage III or stage IV) cervical cancer at diagnosis and patient clinical and
sociodemographic factors were evaluated using multivariable logistic regression.
Logistic regression was done using multiple imputation with chained equations to
account for missing data.

5

2.1.2. Results

There were 984 Women diagnosed with cervical cancer from January 2015 to March
2020 at two tertiary hospitals in Gaborone, Botswana. Four hundred forty women
(44.7%) presented with late-stage cervical cancer, and 674 women (69.7%) were living
with HIV. The mean age at diagnosis was 50.5 years. Women who reported undergoing
cervical cancer screening had lower odds of late-stage disease at diagnosis (OR: 0.63,
95% CI: 0.47-0.84) compared to those who did not report screening. Women who had
never been married had increased odds of late-stage disease at diagnosis (OR: 1.35,
95% CI: 1.02-1.86) compared to women who had been married. Women with abnormal
vaginal bleeding had higher odds of late-stage disease at diagnosis (OR: 2.32, 95% CI:
1.70-3.16) compared to those without abnormal vaginal bleeding. HIV was not
associated with a diagnosis of late-stage cervical cancer. Rural women who consulted a
traditional healer had increased odds of late-stage disease at diagnosis compared to
rural women who had never consulted a traditional healer (OR: 1.61, 95% CI: 1.02-2.55).

2.1.3. Conclusion

Increasing education and awareness among women, regardless of their HIV status, and
among providers, including traditional healers, about the benefits of cervical cancer
screening and about the importance of seeking prompt medical care for abnormal
vaginal bleeding, while also developing support systems for unmarried women, may help
reduce cervical cancer morbidity and mortality in Botswana.

6

2.2. Introduction

Cervical cancer affects women across the globe, with a disproportionately higher burden
of morbidity and mortality in low- and middle-income countries (LMICs) (1). In 2018,
more than 80% of the 311,000 cervical cancer deaths worldwide occurred in LMICs,
predominantly in sub-Saharan Africa (SSA) (1). Cervical cancer is classified as a human
immunodeficiency virus (HIV)-related malignancy, further contributing to the increasing
cancer burden in SSA countries with a high prevalence of HIV(2). Additionally, late-stage
cervical cancer at diagnosis is significantly associated with increased cervical cancer
mortality, and approximately 68% of cervical cancers are diagnosed at a late stage in
SSA (3). Thus, it is paramount to detect cervical cancer at an earlier, more treatable
stage in order to significantly reduce cervical cancer deaths (4, 5).

Cervical cancer screening aims to prevent invasive cancer (6-10). Other clinical and
sociodemographic factors have been associated with late-stage cervical cancer at
diagnosis, particularly in LMICS, including abnormal vaginal bleeding (6, 7, 11, 12), age
at diagnosis (9, 13-15), marital status (6, 15-18), and living in a rural area (7, 15, 16, 18,
19). In addition, the practice of traditional healers has been shown to be associated with
an increase in late-stage cervical cancer at diagnosis (20) and as a barrier to cervical
cancer care in low-resource settings (21).

In Botswana, an upper-middle-income country in SSA, cervical cancer is the leading
cause of female cancer deaths (22, 23). However, there remains a dearth of information
regarding the demographics and clinical factors that contribute to late-stage cervical
7

cancer at diagnosis among women from SSA. Botswana also has a high prevalence of
HIV, with 25.1% of females between 15-49 years of age living with HIV in 2019( 24). In
recent decades, with the growing burden of HIV-related cancers (25), the Botswana
Ministry of Health and Wellness (MOHW) has prioritized reducing the cervical cancer
burden by adapting American Society of Clinical Oncology (ASCO) resource stratified
screening strategies for its citizens, with the majority of cervical cancers being detected
through loop electrosurgical excision procedure or visual inspection with acetic acid (2629). Despite these efforts by the Botswana MOHW, approximately 50% of cervical
cancers are diagnosed at a late stage (6, 30).

This study aims to identify potential clinical and sociodemographic factors associated
with a late-stage diagnosis of cervical cancer in Botswana in order to help inform future
interventions at the community and individual levels aimed at decreasing cervical cancer
morbidity and mortality.

2.3. Methods

2.3.1. Study participants

We abstracted data from questionnaires administered during the initial consult visit and
medical records for women with invasive cervical cancer who had consented to
participate in research studies (30, 31) at Princess Marina Hospital (PMH) and
Gaborone Private Hospital (GPH), two tertiary referral hospitals in the capital city of
Gaborone, between January 2015 and March 2020 (30, 31). GPH houses the sole
chemo-radiation facility in the country. Women diagnosed at either the public hospital
8

PMH or GPH, are treated at GPH, and their treatment is covered under the government
health care system. Women were eligible for this analysis if they were over the age of 18
years, not pregnant, and diagnosed with cervical cancer. Women were excluded if they
were diagnosed with cervical carcinoma in situ or if they had recurrent disease.

2.3.2. Covariates

Data collected at the time of cancer diagnosis included patient/sociodemographic and
clinical factors (i.e., age, marital status, place of residence, history of cervical cancer
screening, ever/never visit with a traditional doctor and/or natural healer, presence of
abnormal vaginal bleeding (including post-coital bleeding/bleeding after vaginal
intercourse), HIV status, and utilization of antiretroviral therapy (ART)). Additional clinical
data was abstracted from medical records regarding clinical factors, such as stage,
pathology, and CD4 count. Place of residence was characterized as urban or rural
based on the sub-district of the participant’s reported residence (32).

Cervical cancer stage at diagnosis was based on the International Federation of
Gynecology and Obstetrics (FIGO) staging system (33, 34). FIGO cervical cancer stages
were dichotomized as early-stage (I-II) and late-stage (III-IV).

2.3.3. Statistical Analyses

Descriptive statistics for each variable of interest were examined for the entire study
sample, and by cervical cancer stage at diagnosis (early vs. late). Differences between
early- and late-stage diseases were examined using Pearson’s chi-squares test for
9

categorical variables, Fisher’s exact test for small sample sizes, and Student t-tests for
continuous variables. Multivariable logistic regression was used to examine potential risk
factors associated with late- versus early-stage disease. Variables included in the
multivariable model were determined based on purposeful selection, review of the
literature, and clinical relevance. We assessed missing data, patterns, and reasons for
missing data. To account for missing data, we performed multiple imputation with
chained equations (MICE) for the multivariable logistic regression model, assuming data
were missing at random (35-37). We also conducted complete case analyses (results
not shown). We further investigated interactions between HIV status and age and HIV
and screening history. We also investigated the use of traditional healers in rural and
urban areas using univariate logistic regression. Additionally, because cervical cancer is
an AIDS-defining malignancy, we examined clinical and sociodemographic differences
between women living with HIV (WLWH) and women without HIV, and performed
multivariable analyses stratified by HIV status. For the analysis of WLWH, CD4 count
and ART use were included as potential risk factors. All statistical analyses were
conducted using STATA 16, and p-values <0.05 were considered statistically significant.

2.4. Results

2.4.1. Patient Characteristics

Between January 2015 and March 2020, 1,007 women were diagnosed with cervical
cancer. We excluded 16 women with prior cervical carcinoma in situ and seven women
with recurrent disease, resulting in the inclusion of 984 women in this study.
Sociodemographic and clinical characteristics are shown in Table 2.1. Four hundred
10

forty (44.7%) of the women included in the study were diagnosed with late-stage cervical
tumors. The mean age at diagnosis was 50.5 years (range 22.4-95.2), 21.0% (n=206)
lived in urban areas, 65.7% (n=646) had never been married, 57.4% (n= 539) reported
previous cervical cancer screening, 69.7% (n=674) were WLWH, and 10.1% (n=95)
reported ever having a visited with a traditional healer. Abnormal vaginal bleeding was
reported in 73.2% (n=720) of women, and 87.3% (n=835) of the cervical cancers were
squamous cell carcinoma (SCC) pathology. Women diagnosed at a late stage were less
likely to report prior screening (50.8% vs. 63.2%, p<0.001) and were also more likely to
report abnormal vaginal bleeding (82.3% vs. 66.3%, p<0.001).

2.4.2. Factors associated with late-stage cervical cancer at diagnosis

Table 2.2 displays factors significantly associated with late-stage cervical cancer at
diagnosis in the imputed multivariable model. MICE was performed to account for
missing data for the variables: stage at diagnosis (n=43), age (n=1), place of residence
(n=3), marital status (n=1), screening history (n=45), HIV status (n=17), and visit with a
traditional healer (n=27). Never being married (OR: 1.35, 95% CI: 1.02-1.86) and
experiencing abnormal vaginal bleeding (OR: 2.32, 95% CI: 1.70-3.16) had an increased
odds of late-stage cervical cancer at diagnosis, while previous cervical cancer screening
was associated with decreased odds of late-stage cervical cancer at diagnosis (OR:
0.65, 95% CI: 0.49-0.85). Results from the complete case analysis were analogous to
the MICE results. No significant interactions were observed between HIV status and age
or between HIV status and screening history.

There were no significant associations between living in an urban residence versus living
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in a rural residence and having ever visited a traditional healer and having late-stage
cervical cancer at diagnosis in the multivariable model. However, in our cohort, more
rural women than urban women (11% vs. 5%) had consulted with a traditional healer.
Table 2.3 shows the association of presenting with late- versus early-stage cervical
cancer at diagnosis when visiting a traditional healer among women living in a rural
residence (OR: 1.61, 95% CI: 1.02-2.55). This increased probability was not observed
among women living in an urban area when visiting a traditional healer.

2.4.3. Characteristics by HIV status

Table 2.4 shows patient characteristics by HIV status. Of the 984 cervical cancer cases,
the HIV status of 967 (98.3%) women was known. Women whose HIV status was
unknown (n=17) were excluded from the HIV stratified analyses. WLWH comprised
69.7% (n=674) of the study population and were significantly younger than women
without HIV (45.8 years vs. 60.5 years, p<0.001). WLWH were also more likely to live in
urban areas (24.0% vs. 14.7%, p=0.001), were more likely to have never been married
(74.0% vs. 47.8%, p<0.001), and were more likely to have been screened for cervical
cancer (61.8% vs. 48.4%, p<0.001) than women without HIV. In addition, WLWH were
more likely to have SCC pathology than women without HIV (88.9% vs. 83.7%,
p=0.020). Among the WLWH, 78.6% (n=429) had a CD4 cell count >250 cells/mm3 at
diagnosis, and 96.2% (n=640) reported being on ART.

Among the WLWH, prior cervical cancer screening showed decreased odds with latestage disease at diagnosis (OR: 0.61, 95% CI: 0.44-0.86), and increased odds with
previous abnormal bleeding symptoms (OR: 2.10, 95% CI: 1.46-3.01). Among women
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without HIV, factors associated with higher odds of late-stage disease at diagnosis
included increasing age (OR: 1.02, 95% CI: 1.00-1.14; p=0.041) and abnormal vaginal
bleeding (OR: 3.06, 95% CI: 1.52-5.71) (Table 2.5). Results of complete case analyses
by HIV status were similar to the imputed results.

2.5. Discussion

This large study of women with cervical cancer in Botswana aimed to identify potential
clinical and sociodemographic factors associated with a late-stage diagnosis of cervical
cancer in Botswana. Our study showed that prior cervical cancer screening was
associated with decreased odds of having late-stage cervical cancer at diagnosis,
whereas experiencing abnormal vaginal bleeding and having never been married were
associated with an increased odds of having late-stage cervical cancer at diagnosis.
Having HIV was not associated with having late-stage cervical cancer at diagnosis.
Furthermore, results suggested that women living in rural areas who visited a traditional
healer were more likely to be diagnosed with late-stage cervical cancer.

Screening has been shown to lead to an earlier diagnosis of cervical cancer in highincome countries with established screening programs, and screening has also been
shown to be effective in low resource settings (7, 9, 38). With the growing burden of HIVrelated cancers in recent decades (25), the Botswana MOHW has prioritized reducing
the cervical cancer burden through implementing and supporting a national cervical
cancer screening program as part of the HIV care continuum (23, 27, 28, 39, 40). A prior
retrospective study by Nassali et al. (2018) reviewed 149 cervical cancer patients
admitted to PMH from August 2016 to February 2017, which may include some overlap
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with our study sample. In that study, Nassali et al. defined late-stage cervical cancer as
FIGO stage IB2-IVB, and found an increased odds of presenting with late-stage tumors
in patients not previously screened for cervical cancer. Additionally, two qualitative
studies in Botswana (41, 42) have shown that lack of knowledge regarding the benefits
of screening for cervical cancer can delay diagnosis. Our study provides further
evidence supporting the finding that screening decreases the odds of presenting with
late-stage cervical cancer at diagnosis when implemented in a low resource setting.

Early-stage asymptomatic cervical cancer can be detected through screening, but in the
absence of screening, patients with cervical cancer can present with clinical symptoms
including abnormal vaginal bleeding and post-coital bleeding (34). Reports of
symptomatic bleeding and its association with late-stage disease at diagnosis in low
resource settings have been inconsistent in the literature (6, 7, 11, 12). Studies have
shown an increased risk (6), no association (7), and a decreased risk (11, 12). In Nepal,
a decreased risk for having late-stage cervical cancer at diagnosis was noted if the
symptoms of bleeding were reported first to the woman’s husband, who might
encourage his wife to seek medical care. In Morocco, the decreased association
between having late-stage cervical cancer at diagnosis and having symptomatic
bleeding was hypothesized to be due to understanding the severity of bleeding as a
cervical cancer symptom and seeking medical care without delay. Two studies in
Botswana (20, 43) showed that the perception of symptom severity was related to
having advanced stage cervical cancer at diagnosis and to a having a delay in health
seeking behavior. In our study, reporting gynecological bleeding symptoms, including
previous abnormal vaginal bleeding and/or post-coital bleeding, was associated with a
two-fold increase in the odds of presenting with late-stage cervical cancer. These results
14

support increasing awareness regarding abnormal vaginal bleeding and post-coital
bleeding as indications of cervical cancer and emphasizing the need to seek medical
care as soon as possible. In addition, these findings support screening asymptomatic
women to be able to diagnose cervical cancer at an early stage.

In our study, there was no significant difference between WLWH and women without
HIV with regard to their likelihood of presenting with advanced state cervical cancer.
Some studies have recognized HIV as a risk factor for late-stage cervical cancer at
diagnosis (16, 19), yet other studies (6, 44) have reported no association with HIV and
late-stage cervical cancer at diagnosis. The role of HIV in the diagnosis of late-stage
cervical cancer remains unclear and should be investigated further. When comparing
WLWH and women without HIV in our cohort, the WLWH were younger, were more
likely to have undergone cervical cancer screening, had more often lived in urban areas,
and were more likely to be married or to have been married than women without HIV.
Also, in the subgroup analyses, associations with late-stage cervical cancer at diagnosis
differed between the two subgroups of WLWH versus women without HIV. Increasing
age was significantly associated with late-stage cervical cancer at diagnosis in women
without HIV, but not in WLWH. WLWH with a history of cervical cancer screening had
lower odds of presenting with late-stage cervical cancer at diagnosis; however cervical
cancer screening was not significantly associated with late-stage cervical cancer at
diagnosis in women without HIV. In Botswana, cervical cancer screening programs have
been implemented as part of the HIV care continuum for women, making it is plausible
that women without HIV do not access screening services to the same extent as WLWH.
Therefore, increasing screening services among women without HIV could reduce the
prevalence of late-stage cervical cancer at diagnosis for these women.
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Our study saw a decrease in late-stage cervical cancer cases among women who had
been married. Similarly, a study from Nepal (11) noted that married women with
symptomatic bleeding were less likely to present with a late-stage cervical cancer
because husbands may encourage their wives to seek medical care. A study by Ibrahimi
and Pinheiro (2017) in the United States reported that being married was an
independent predictor of a more favorable prognosis of cervical cancer (45). While some
studies have identified being unmarried as a risk factor for having late-stage cervical
cancer at diagnosis (6, 17, 18), other studies have found no such association (15, 16).
Reasons for this association are unclear. Future studies investigating differences in
financial, emotional, and sociocultural marital structures and the impact on prompt
cancer diagnosis are warranted. These inconsistencies could be attributed to differences
among the sociocultural marital structures and support systems across countries, which
need to be explored further.

Areas of residence may also impact health care. For example, living in a rural area
versus living in an urban area has been investigated as a potential contributing factor for
women with late-stage cervical cancer at diagnosis (7, 15, 16, 18, 19). A study in Sudan
reported that an increased risk for having late-stage cervical cancer at diagnosis was
associated with living in a rural setting versus living in an urban setting (15), but this
result was not seen in our cohort, nor was any such association reported in other studies
in Ghana (7), Florida (18), Ethiopia (19), or SSA (15). The use of traditional healers has
been shown to be associated with late-stage cervical cancer at diagnosis in Botswana
(20) and as a barrier to cervical cancer care in Uganda (21). In Botswana, over 95% of
traditional healers live in rural areas (46), and thus women living in a rural area may be
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more likely to consult with traditional healers as their first choice for healthcare. In our
study, when examining only women living in a rural area, those who visited a traditional
healer had a higher odds of presenting with late-stage cervical cancer. Points of
intervention in rural areas could include educating traditional healers to recognize
symptoms of cervical cancer in order to facilitate a referral for diagnosis and treatment.

This large study investigating late-stage cervical cancer at diagnosis in Botswana
includes detailed demographic and clinical information on patients in Botswana collected
over a five-year period, but it does have several potential limitations and challenges. It is
important to note that, due to the cross-sectional study design, no decisive conclusions
can be made about the temporality or causality among the study variables and late stage
diagnosis. Patients were enrolled at PMH, a public tertiary hospital with oncology
services, and at GPH, a private tertiary hospital with the only chemo-radiation oncology
center in Botswana; thus, all patients who need radiotherapy should be sent to GPH. We
were unable to account for patients who were not diagnosed with or treated for cervical
cancer outside of these two facilities. In addition, the study collected data at the time of
diagnosis and is therefore subject to recall bias, social desirability bias, and potential
unmeasured confounding and missing data. Unfortunately, due to the retrospective
nature of the study, we lacked important information and were unable to account for
confounders including education level, knowledge and awareness of cervical cancer,
and cervical cancer screening. To account for any bias due to missing data, we
conducted MICE for the primary analysis (35-37). Results using MICE were similar to the
complete case analysis. Although our findings represent a large proportion of cervical
cancer cases in Botswana, they do not represent all cervical cancer patients in
Botswana and are not generalizable to the entire country.
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2.6. Conclusion

Our results highlight patient level factors associated with late-stage cervical at diagnosis
and indicate potential areas for intervention to mitigate the cervical cancer burden in
Botswana. Our findings show that cervical cancer screening for women in Botswana is
associated with the early detection of cervical cancer, particularly in women with HIV.
Future efforts to include women without HIV and women who have not been married in
cervical cancer screening efforts could result in the earlier detection of cervical cancer in
these groups. Future early cervical cancer detection efforts should emphasize cancer
symptom awareness and early detection through cervical cancer screening, and should
also include traditional healers in the cancer care continuum.
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Table 2. 1. Clinical and demographic characteristics of the study population by earlyversus late-stage cervical cancer diagnosis
Study
Population
Variable

Early
Stage

Late
Stage

N

%

N

%

N

%

984

100

501

50.9

440

44.7

Pvalue**

Age category

<30
>30-40
>40-50
>50-60
>60-70
>70

13
188
369
183
148
82

1.3
19.1
37.5
18.6
15.1
8.3

7
98
191
98
66
40

1.4
19.6
38.2
19.6
13.2
8.0

6
83
159
83
70
39

1.4
18.9
36.1
18.9
15.9
8.9

0.88

Residence

Rural
Urban

775
206

79.0
21.0

390
110

78.0
22.0

359
80

81.8
18.2

0.15

Marital status

Never married/single
Married
Divorced
Widowed

646
226
13
98

65.7
23.0
1.3
10.0

315
124
10
51

63.0
24.8
2.0
10.2

307
89
3
41

69.8
20.2
0.7
9.3

0.08

Previous cervical
cancer screening

Never screened
Screened

400
539

42.6
57.4

177
304

36.8
63.2

205
212

49.2
50.8

<0.001*

Visit with a natural/
traditional healer

No
Yes

845
95

89.9
10.1

443
45

90.8
9.2

378
50

88.3
11.7

0.22

HIV

Negative

293

30.3

154

31.2

128

29.6

0.59

Positive

674

69.7

340

68.8

305

70.4

FIGO stage

I
II
III
IV

166
335
350
90

17.6
35.6
37.2
9.6

166
335
-

33.1
66.9
-

350
90

79.5
20.5

--

Pathology

SCC
Adenocarcinoma
Invasive ductal
Other
Unknown/other

835
66
4
40
12

87.3
6.9
0.4
4.2
1.2

422
41
1
20
6

86.1
8.4
0.2
4.1
1.2

384
22
3
15
4

89.7
5.1
0.7
3.5
0.9

0.29

264
720

26.8
73.2

169
332

33.7
66.3

78
362

17.7
82.3

<0.001*

Abnormal vaginal
bleeding

Not reported
Reported

*p<0.05
**p-value for differences between early stage and late stage
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Table 2. 2 Imputed multivariable analysis of factors associated with late-stage cervical
cancer
Late Stage at Diagnosis

95% CI

P-value

Age

Adjusted
Odds
Ratio
1.01

1.00 -1.03

0.067

Urban vs. rural residence

0.78

0.55-1.10

0.153

Never married/single vs. married/widowed/divorced

1.35

1.02-1.86

0.044*

Cervical cancer screening vs. never screened

0.65

0.49-0.85

0.002*

Visit with a natural healer (Yes/No)

1.19

0.77-1.84

0.434

HIV seropositive vs. seronegative

1.37

0.97-1.93

0.077

Abnormal vaginal bleeding (Yes/No)

2.32

1.70-3.16

<0.001*

95% CI: 95% Confidence Interval
*p<0.05

Table 2. 3 Visit with a traditional healer in a rural setting in women with late- versus
early-stage cervical cancer

Visit with a traditional
healer
No visit with a
traditional healer

Early Stage
35 (9%)

Late Stage
49 (14%)

346 (91%)

301 (86%)

OR
1.61

OR: Odds Ratio, 95% CI: 95% Confidence Interval
*p<0.05
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95% CI
1.02-2.55

P-value
0.043*

Table 2. 4 Clinical and demographic characteristics of the study population by HIV status
HIV Negative
Variable

HIV Positive

N

%

N

%

293

30.3

674

69.7

<30
>30-40

2
23

0.7
7.9

11
165

1.6
24.5

>40-50
>50-60
>60-70
>70

44
60
98
65

15.1
20.5
33.6
22.3

324
119
47
8

48.1
17.7
7.0
1.2

250
43
140
91
3
59

85.3
14.7
47.8
31.1
1.0
20.1

511
161
498
132
9
34

76.0
24.0
74.0
19.6
1.3
5.1

<0.001*

Marital status

Rural
Urban
Never married/single
Married
Divorced
Widowed

Previous cervical
cancer screening

Never screened
Screened

143
134

51.6
48.4

248
401

38.2
61.8

<0.001*

Visit with a
traditional healer

No
Yes

250
35

87.7
12.3

599
60

90.9
9.1

0.140

FIGO Stage

I
II
III
IV

48
106
100
28

17.0
37.6
35.5
9.9

115
225
245
60

17.8
34.9
38.0
9.3

0.83

Pathology

SCC
Adenocarcinoma
Invasive ductal
Other
Vascular invasion
Unknown

239
31
1
9
0
5

83.9
10.9
0.4
3.2
0
1.8

583
33
3
30
1
6

88.9
5.0
0.5
4.6
0.2
0.9

0.022*

Abnormal vaginal
bleeding

Not reported
Reported

68
225

23.2
76.8

192
482

28.5
71.5

0.089

CD4

<250 cells/mm3
>250 cells/mm3

-

-

117
429

21.4
78.6

--

ART**

No
Yes

-

-

25
640

3.8
96.2

--

Age categories

Residence

Category

*p<0.05
**ART: Anti-retroviral therapy
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p-value
<0.001*

<0.001*

Table 2. 5 Imputed multivariable subgroup analyses of women living with HIV and
women without HIV
Late Stage at Diagnosis

aOR

95% CI

P-value

WLWH n=674

aOR

95% CI

P-value

Women without HIV n=293

Age

1.01

0.99-1.02

0.480

1.02

1.00-1.04

0.041*

Urban vs. rural residence

0.79

0.54-1.16

0.234

0.88

0.43-1.81

0.730

Never married/single vs.
married/widowed/divorced
Cervical cancer screening vs.
never screened
Visit with a traditional healer
(Ye/No)
Abnormal vaginal bleeding
(Yes/No)
CD4 count <250 vs. >250

1.23

0.85-1.79

0.273

1.59

0.94-2.70

0.087

0.61

0.44-0.86

0.004*

0.80

0.48-1.35

0.413

0.95

0.55-1.65

0.864

1.52

0.71-3.26

0.276

2.10

1.46-3.01

<0.001*

3.06

1.52-5.71

0.001*

1.15

0.73-1.79

0.546

Anti-retroviral treatment
(Yes/No)

1.11

0.46-2.65

0.821

aOR: adjusted odds ratio, 95% CI: 95% Confidence Interval
*p<0.05
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CHAPTER 3. Evaluating the geographic distribution of cervical cancer patients referred
to a multidisciplinary tumor clinic in Gaborone, Botswana

3.1. Abstract

3.1.1. Background

In Botswana, cervical cancer is the leading cause of cancer death for females. With
limited resources, Botswana is challenged to ensure equitable access to advanced
cancer care. The capital, Gaborone, houses the only gynecologic oncology multidisciplinary team (MDT) and the one chemoradiation facility in the country. We aimed to
identify areas where fewer women were presenting to the MDT clinic for care.

3.1.2. Methods

This cross-sectional study examined cervical cancer patients presenting to the MDT
clinic between January 2015 and March 2020. Patients were geocoded to residential
sub-districts to estimate age-standardized presentation rates. Global Moran’s I and
Anselin Local Moran’s I tested the null hypothesis that presentation rates occurred
randomly in Botswana. Community- and individual-level factors of patients living in subdistricts identified with higher (HH) and lower (LL) clusters of presentation rates were
examined using ordinary least squares with a spatial weights matrix and multivariable
logistic regression, respectively, with α level 0.05.
27

3.1.3. Results

We studied 990 patients aged 22-95 (mean: 50.6). Presentation rates were
geographically clustered across the country (p=0.01). Five sub-districts were identified
as clusters, 3 HH and 2 LL (mean presentation rate: 35.5 and 11.3, respectively).
Presentation rates decreased with increased travel distance (p=0.033). Patients in LL
sub-districts more often reported abnormal vaginal bleeding (aOR: 5.62, 95% CI: 1.3124.15) compared to patients not in LL sub-districts. Patients in HH sub-districts were less
likely to be living with HIV (aOR: 0.59; 95% CI: 0.38-0.90) and more likely to present with
late-stage cancer (aOR: 1.78; 95%CI: 1.20-2.63) compared to patients not in HH subdistricts.

3.1.4. Conclusions

This study identified geographic clustering of cervical cancer patients presenting for care
in Botswana, and highlighted sub-districts with disproportionately lower presentation
rates. Identified community- and individual level-factors associated with low presentation
rates can inform strategies aimed at improving equitable access to cervical cancer care.
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3.2. Introduction

Cervical cancer is a preventable malignancy affecting women worldwide. Mortality from
cervical cancer is disproportionately higher in low resource settings (1, 2). In 2020, there
were an estimated 604,000 new cervical cancer cases and 342,000 deaths, with the vast
majority of deaths occurring in low resource settings, predominantly in sub-Saharan
Africa (SSA) (1-3). The majority of cervical cancer deaths in these settings can be
attributed to poor access to prevention, screening, and the appropriate treatment (4-7).
In Botswana, a upper-middle income country in SSA, cervical cancer is the most
commonly diagnosed cancer and leading cause of cancer death for females (8). The
population of approximately 2.3 million people currently has over 700,000 women over
the age of 20 at risk for developing cervical cancer (9). The majority of cervical cancers
are caused by Human Papilloma Viruses (HPV) (10), and co-infection of HPV and
Human Immunodeficiency Virus (HIV) further increases cervical cancer risk (11, 12).
With the third highest HIV prevalence in the world, cervical cancer prevention, screening,
and treatment are a national priority in Botswana (13).

With limited resources, Botswana’s cancer control program is challenged to ensure
equitable access to advanced health care. A critical factor that affects cancer outcomes
is a delay in a diagnosis which can result in the progression of a malignant tumor (1416). Thus, delayed access to care is important when considering cancer morbidity and
mortality. One aspect of access is geographic accessibility. Botswana is a sparsely
populated country with only one clinic with a multi-disciplinary team (MDT) for
gynecological oncology located in capital city, Gaborone. The MDT clinic includes
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Botswana’s only gynecological oncologist and the one chemoradiation facility in the
country capable of providing standard of care, including staging and treatment, for
cervical cancer patients diagnosed with locally advanced disease (17, 18).
Gaborone is located in the southeast corner of the country, over 1000 km away from the
furthest residential areas. Geography, therefore, may be a particularly important barrier
for accessing care (16). Geographic information systems (GIS), that enable capturing
and analyzing spatial and geographic data from a wide range of sources in conjunction
with one another, is an efficient and powerful methodical framework to investigate the
role of geography and health in a population (19, 20). The use of GIS technology and
methods is rapidly evolving. GIS can help identify areas of limited access and help direct
resources/planning efforts as well as illuminate factors that contribute to the bigger
picture of public health. In low resource settings these methods can contribute to the
limited cancer information available (21-23). To our knowledge this is the first study to
apply GIS methods to investigate the geographic distribution of cervical cancer patients
presenting for care in Botswana.

The World Health Organization’s projected incidence of cervical cancer in Botswana for
2020 calculated using the Botswana National Cancer Registry (8) data from 2004-2008
is 374 cases (24). Given one comprehensive MDT clinic where all women diagnosed
with locally advanced cervical cancer should be referred to for treatment, we would
anticipate over 300 cervical cancer cases to be referred to the MDT clinic per year.
However, for the past five years the MDT clinic has averaged less than 200 cases/year
(range: 96-256). We hypothesize that due to the lack of equitable access, not all women
diagnosed with cervical cancer throughout Botswana are presenting for staging and
treatment to the MDT clinic in Gaborone, and thus the rate of patients presenting for
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treatment is not random throughout Botswana. We apply GIS to identify areas with high
or low presentation rates and highlight areas where suboptimal patterns of care exist.
Highlighting areas with low presentation rates and understanding community- and
individual-level characteristics associated with living in areas with low presentation rates
can inform strategies for more equitable distribution of resources and highlight areas in
need of improved access to cancer treatment facilities.

3.3. Methods

3.3.1. Study participants

This cross-sectional study included biopsy proven cervical cancer patients referred to
the MDT clinic between January 2015 and March 2020. The MDT clinic, located within
Princess Marina Hospital (PMH), coordinates care for all gynecological oncology
patients referred to the two tertiary hospitals in Gaborone: PMH and Gaborone Private
Hospital (GPH) (18). Eligible patients were over the age of 18, not pregnant, and were
not diagnosed with cervical carcinoma in situ or had recurrent disease.

3.3.2. Primary outcome measure

Our primary outcome was measuring the rate of cervical cancer patients presenting to
the MDT clinic for staging and/or treatment, henceforth referred to as ‘presentation
rate’. To detect areas in Botswana with disproportionately high or low presentation
rates, we defined our geographic unit of analysis as administrative sub-districts in
Botswana. We used an available shapefile from the USCB (9) that defined the 2nd31

order administrative boundaries for 28 sub-districts throughout the country. The USCB
also defines 519 3rd order administrative divisions described as “villages and
associated localities” (9). We abstracted each patient’s residential village from the
questionnaire and geocoded each patient to one of USCB’s identified 519 villages (9).
To calculate the presentation rates, we aggregated cervical cancer patients per village
and identified the appropriate administrative sub-district for which the patient lived. The
denominator for each sub-district consisted of the total female population for patients
20 years and older from January 2015 to March 2020 (9). We age-standardized the
presentation rates using the overall Botswana female age distribution. Presentation
rates by sub-district were visually inspected using choropleth maps for geographic
variation.

3.3.3. Covariates

Sub-district-level covariates included HIV prevalence, population density, and travel
distance to the MDT clinic in Gaborone. The HIV prevalence for each sub-district was
obtained from the Botswana AIDS Impact Survey IV (25). Population density, an
indicator of urban or rural areas, was calculated using the projected population relative
to the polygon area per sub-district using projected estimates and the polygon area from
the shapefile from the USCB (9). Euclidian travel distance was measured in Google
maps (26) using the centroid of each sub-district to the MDT clinic in Gaborone.

Data collected from the questionnaire administered at first visit to the clinic included
patient sociodemographic and clinical factors (age, marital status, residence, history of
cervical cancer screening, ever/never visit with a traditional doctor and/or natural healer,
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presence of abnormal vaginal bleeding (including post-coital bleeding/bleeding after
vaginal intercourse), and HIV status). Additional clinical data was abstracted from
medical records for cervical cancer stage at presentation based on the International
Federation of Gynecology and Obstetrics (FIGO) staging system (27, 28).

3.3.4. Geographic Analysis

To assess geographic patterns of presentation rates both nationally and locally, we
employed Global Moran’s I and Anselin local index of spatial autocorrelation statistics,
respectively (29, 30). Global Moran’s I test was conducted to assess if presentation rates
across the country were clustered, dispersed, or random (null hypothesis). A positive
spatial autocorrelation result indicates clustering, describing sub-districts with similar
presentation rates within close geographic proximity to each other. Negative spatial
autocorrelation reveals dispersion, noting sub-districts with dissimilar presentation rates
were closer in geographical proximity in a manner that was not random. A null result
indicates presentation rates across Botswana is random.

For the geographic analysis we defined neighbors using queen’s contiguity matrix (31)
and conducted permutation tests with 999 simulations for significance. Using this
weights matrix, the Global Moran’s I test enables presentation rates of each sub-district
to be correlated with the mean presentation rates of neighboring sub-districts (spatial
autocorrelation), thereby accounting for spatial dependence in presentation rates
between sub-districts.
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Moran’s I analysis does not detect local patterns of spatial association (29). To
investigate local patterns of presentation rates for each sub-district, we employed the
local index of spatial autocorrelation (30). This approach determines for each individual
(target) sub-district if presentation rates are uniformly similar or disproportionately high
or low relative to the mean presentation rates of that sub-district’s neighbors, once again
defined by Queen’s contiguity matrix (31). Permutation tests with 999 simulations were
conducted and statistically significant clusters (similar presentation rates) or outliers
(dissimilar presentation rates) were identified with 95% confidence intervals. A significant
result revealed one of four possible categories for each sub-district, two types of clusters
or two types of outliers. A high-high (HH) cluster indicated target sub-districts with high
presentation rates were surrounded by neighboring sub-districts with high presentation
rates, and conversely low-low (LL) clusters identified target sub-districts with low
presentation rates surrounded by neighboring sub-districts with low presentation rates.
High-low (HL) or low-high (LH) outliers indicated an inverse relationship between the
target sub-district presentation rates and the mean of their neighbor’s presentation rates.

3.3.5. Statistical Analysis

Simple ordinary least squares (OLS) regression investigated the relationship of agestandardized presentation rates across the country with sub-district level community
factors. If Moran’s I identified significant autocorrelation, we accounted for nonindependence of presentation rates in our multivariable OLS regression mode using a
spatial weights matrix (32) to investigate associations with sub-district level variables
(HIV prevalence, population density, and travel distance).
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Lastly, we investigated individual-level clinical and demographic characteristics among
cervical cancer cases living in a clustered (HH/LL) or outlier (HL/LH) identified subdistrict compared to patients living in any other sub-district. Univariate individual level
differences were assessed using student t-tests, chi-squared tests, and fishers exact
tests as appropriate. Additionally, multivariable logistic regression models determined
the magnitude of associations for patients living in identified LL or HH sub-districts
versus patients not living in these sub-districts, while adjusting for demographic and
clinical characteristics. Adjusted odds ratios and 95% confidence intervals with a cut
off α value 0.05 determined significant associations. We performed geospatial analysis
in ArcGIS version 10.6.1 (Esri, Redlands, CA) and open source GeoDa software (32),
and conducted all Statistical analysis in STATA 16.1 (College Station, TX).

3.3.6 Alternative methods

Alternative methods using village as the unit of analysis was also explored and is
described in Appendix A.

3.4. Results

One thousand nineteen cervical cancer patients presented to the MDT clinic between
January 2015 and March 2020. Nineteen patients (1.8%) diagnosed with cervical
carcinoma in situ and 7 (0.7%) patients with recurrent disease were excluded. Three
patients (0.3%) did have village of residence, thus 990 cervical cancer patients were
geocoded to one of the 28 sub-districts. Sociodemographic and clinical characteristics
are shown in Table 3.1. Cervical cancer patients had a mean age of 50.6 years at time
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of presentation (range: 22.4--95.2). The overall presentation rate was 27.2 per 100,000
women (IQR: 12.5-35.0) for our study period. Age-standardized presentation rates by
sub-districts are visually presented in a choropleth map (Figure 3.1). Crude and agestandardized presentation rates are presented in Table 3.2.

Positive spatial autocorrelation was observed (Global Moran’s I=0.249; p=0.014),
identifying positive geographic clustering of cervical cancer rates across the country.
Anselin local Moran’s I identified specific sub-districts where presentation rates were
disproportionately high or low relative to their neighbors. Of the 28 sub-districts, 5
significant clustered (17.8%) HH or LL sub-districts were identified (Figure 3.2). No
outliers (HL or LH sub-districts) were found. Two sub-districts were determined as HH
clusters: Kgalagadi South and Southern (rate per 100,000 women: 29.8 and 41.2,
respectively). Three sub-districts were determined as LL clusters: Ngamiland West,
Ngamiland East, and Ghanzi (rate per 100,000 women: 9.5, 13.8, and 10.6
respectively). Community-level factors for HH and LL sub-district clusters are shown in
Table 3.3. HH sub-disricts had a mean presentation rate of 35.5 per 100,000 women
and LL sub-districts had a mean presentation rate of 11.33 per 100,000 women.
Population density was 8.82 per km2 for HH sub-districts and 1.94 km2 for LL subdistricts. For HH sub-distritcs, the mean HIV prevalance for females was from 11.45
per 100,000 women and for LL sub-districts 15.27 per 100,000 women.

Results from OLS regression showed a significant association between presentation
rates across Botswana with travel distance (coefficient: -0.020, p=0.034) to Gaborone,
but no association with population density or HIV prevalence. Using the spatial weights
matrix, multivariable OLS found that presentation rates across Botswana increased with
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decreased travel distance to Gaborone (adjusted coefficient: -0.026, p=0.033). No
significant associations were found for HIV prevalence or population density (Table 3.4).
Univariate individual level differences for patients living in an LL sub-district compared
to not living in an LL sub-district, and differences for patients living a HH sub-district
compared to not living in a HH sub-district, were assessed using student t-tests and
chi-squared tests (Table 3.5). Women presenting from LL sub-districts were more
commonly HIV positive (p=0.025), and more often reported abnormal vaginal bleeding
(p=0.008) than women not presenting from LL sub-districts. Women presenting from
HH sub-districts were older (p=0.010), more commonly HIV negative (p<0.001), and
more often presented with late stage disease (p=0.009) compared to women not
presenting from HH sub-districts.

Additionally, multivariable logistic regression identified individual level factors
associated with patients living in sub-districts with disproportionate presentation rates.
Patients living in LL sub-districts compared to patients not living in a LL sub-district
more often reported experiencing abnormal vaginal bleeding (aOR: 5.88, 95% CI:
1.37-25.23) and were more likely to be HIV positive, though this did not reach
statistical significance (aOR: 3.29; 95% CI: 0.97-11.17). Due to the limited number of
patients presenting from LL sub-districts these results should be interpreted with
caution and considered exploratory. Patients living in HH sub-districts were less likely
to be living with HIV relative to those not living in HH districts (aOR: 0.46; 95% CI:
0.27-0.78) and more likely to be diagnosed with late-stage cervical cancer (aOR: 1.85;
95%CI: 1.19-2.87) compared to patients not living in a HH sub-district (Table 3.6).
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3.5. Discussion

This study reveals non-random geographic patterns of patients with cervical cancer
throughout Botswana presenting to the MDT clinic in Gaborone. We identified specific
areas of the country with disproportionately high and low presentation rates, indicating
that areas with low presentation rates may have poor access to the one
comprehensive care MDT clinic in Botswana, and areas with high presentation rates
have better access to the MDT clinic. Patients living in sub-districts with low
presentation rates were more likely to present with abnormal vaginal bleeding, and
patients living in sub-districts with high presentation rates were more likely to be HIV
negative and more likely to present with late stage disease. Identifying community and
individual level factors associated with access to comprehensive cervical cancer care
gives national health programs insight when developing strategies that target areas
and populations being underserved by health facilities. These strategies will be key in
preventing and controlling the emerging cervical cancer burden in Botswana.

In the literature, GIS methods have been used to examine local and regional variation
of disease and to understand equity of access to care, as significant clustering of
diseases may indicate potential inequity in access (33-35). We carried out this study
with the theory that geographic differences in presentation rates does not reflect the
incidence or prevalence of cervical cancer, but rather differences in patients accessing
and presenting for treatment. Co-infection of HIV and HPV increase risk of cervical
cancer (11, 12), but our results identified no association between sub-district-level HIV
prevalence and presentation rates across the country. This supports the hypothesis
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that presentation rates are not likely a reflection of cervical cancer incidence or
prevalence, but rather due inequity of access.

The literature has also reported that access to care is an important factor to for cancer
survival, particularly in low resource settings (7, 36, 37). As reported by Penchansky
and Thomas (38), access is multi-dimensional and consists of availability, accessibility,
accommodation, affordability and acceptability. It could be inferred that sub-districts
with high presentation rates have greater access than other sub-districts to care. One
dimension of access is accessibility, or travel distance to the health center. Accounting
for spatial correlation, our results found that greater/shorter travel distance to the MDT
clinic in Gaborone was associated with higher/lower presentation rates. Sub-districts in
the Southern region of Botswana with closer proximity to Gaborone had increased
presentation rates, while sub-districts with low presentation rates were identified in the
North West, further away and separated from Gaborone by the Central Kalahari Game
Reserve, making travel to Gaborone much more challenging. Our study suggests that
travel-distance accessibility to the MDT clinic in Gaborone presents a major barrier to
care for cervical cancer patients in specific areas of the country.

Geographic accessibility is one factor impacting access to care, and a more detailed
understanding of this and other barriers of access in areas with low presentation rates
could inform strategies to increase the number of cervical cancer cases presenting for
care. Of note, sub-districts with higher presentation rates were not geographically the
closest sub-districts to Gaborone, and Gaborone itself was not an area within a highhigh cluster, further signifying that additional dimensions of access besides traveldistance accessibility that are influencing access to care. For example, another barrier
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of access is knowledge. Studies have shown that lack of knowledge regarding cervical
cancer and cervical cancer screening as an identified barrier for cervical cancer care in
Botswana, thus knowledge may differ according to geography (14, 39). Tapela et. al.
demonstrated a successful strategy implemented in Botswana at the health-care level
led to improved knowledge for primary care providers and reduced health system
delays (40). Understanding knowledge gaps in areas with low presentation rates could
potentially increase the number of cervical cancer patients presenting for care.

Previous studies in Botswana have shown that the lack of understanding of symptom
severity is associated with a delay in seeking care (14, 39). Patients in sub-districts with
low rates more often reported abnormal vaginal bleeding, indicating that these patients
may not receiving prompt medical attention and are not being referred until later stages
when they are symptomatic. It may be beneficial to assess awareness of symptoms in
areas with low presentation rates as well as areas with high presentation rates, to
understand if there is a difference at the provider or patient level in understanding
abnormal vaginal bleeding as a symptom of cervical cancer. These findings also support
previous reports to increase awareness, education, and screening for asymptomatic
women in order to be able to detect cervical cancer at an earlier stage and improve
outcomes (14, 39).

Our study also found that sub-districts with high presentation rates were associated
with cervical cancer cases more likely to present at a late-stage. While this may seem
counter intuitive, due to the lack of comprehensive screening for asymptomatic
women, cases throughout the country are more likely to be diagnosed at a late-stage.
Most studies have found for SSA, including Botswana, that more than half of cervical
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cancer cases are diagnosed at a late-stage (5, 14, 41). We could hypothesize that for
sub-districts with higher access to Gaborone, patients diagnosed at a late-stage when
symptoms are present and morbidity is increased, may still be able to present to the
MDT clinic for staging and treatment. However, areas with lower access may not be
able to present to the MDT clinic for treatment before succumbing to their disease, and
could be a reason why less late-stage cancers would be presenting from areas with
lower access. While our work does not directly address this inconsistency, future work
could investigate the true prevalence of cervical cancer and the influence of morbidity
in areas with low presentation rates.

In Botswana, cervical cancer screening and care have been implemented as part of the
HIV care continuum (42), and therefore women living with HIV are likely to have
increased health visits, more contact with health providers, and increased health literacy.
Sub-districts with higher presentation rates, despite having no significant difference in
community level HIV prevalence, had more HIV negative women present for treatment.
A previous study also speculated that access to care may be differential according to
HIV status in Botswana (43). Thus, it is plausible that HIV negative women in subdistricts with lower presentation rates may be limited in terms of cervical cancer
awareness, screening, and contact with health care services. Increasing health literacy
and other health services among women without HIV, particularly in areas with low
presentation rates, could increase the number of patients presenting for cervical cancer
care.

Our study, the first to apply GIS to assess patterns of cervical cancer patients presenting
for treatment in Gaborone, has limitations. It is important to note that, due to the cross41

sectional study design, no decisive conclusions can be made about the temporality or
causality among the individual-level study variables. Also, those not seeking advanced
medical care for symptoms of cervical cancer at the MDT clinic would not be captured in
this cohort. This potential for selection bias would result in underrepresentation of
cervical cancer in our dataset and could vary by geography, travel time and other factors
that could have impacted our results. For example, if patients with early-stage disease
were being surgically treated for cervical cancer outside of the MDT clinic in areas with
low presentation rates, this could bias our results towards the null and reject our
hypothesis that less patients are presenting for care from these areas. In addition,
community- and individual-level factors, such as poverty, socioeconomic status,
education level and employment were not accounted for. These social determinants of
health, likely to be geographically dependent, also influence various aspects of access.
Future work to investigate these factors could contribute to a better understanding of
barriers of access in sub-districts with low presentation rates. Not accounting for these
additional confounding or modifying factors could lead to a misinterpretation of our
results. For example, if there is less awareness in areas further away from Gaborone,
this lack of knowledge could explain the low presentation rates instead of traveldistance. Future work accounting for additional dimensions of access is important to truly
understand the barriers in areas with low presentation rates.

Our results reveal areas in Botswana with low presentation rates and where women
living with cervical cancer may not be presenting for appropriate cervical cancer care.
Our results also hypothesize about community and individual level factors that could be
limiting access to health care for areas with low presentation rates. Our results indicated
travel-distance is a potential barrier to accessing cervical cancer care. We also identified
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additional potential areas for intervention to mitigate the cervical cancer burden at the
individual level, including increasing efforts for women without HIV to assess and
improve knowledge related to cervical cancer and cervical cancer screening. Future
efforts could be increased for awareness campaigns and cervical cancer screening
efforts to include women without HIV. Additionally, early cervical cancer detection efforts
should also emphasize cancer symptom awareness and education about the steps
women should take if they experience these symptoms.

3.6. Conclusion

Botswana carries a heavy burden of cervical cancer, access to adequate treatment is
essential to reduce disease and save lives. Improving equitable access to cervical
cancer treatment for women living in sub-districts with lower rates of cervical cancer
patients presenting for care should be prioritized to help reduce the morbidity and
mortality of cervical cancer.
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Table 3.1. Community and individual level characteristics of sub-districts and the study
population
Community level factors

N=28
Mean
290.74
417.80
17.82

Standard Deviation
644.09
320.71
3.89

Age

N=990
Mean
50.6

Range
22.4-95.2

HIV Positive
HIV Negative

Number Percent
680
69.9%
293
30.1%

Married/widowed/divorced
Never married/single

339
651

34.2%
65.8%

Early Stage (stage I/II)
Late Stage (stage III/IV)

490
420

53.8%
46.2%

Cervical cancer screening ever
Cervical cancer screening never

546
400

57.7%
42.3%

Visit with a traditional healer (Yes)
Visit with a traditional healer (No)

98
867

10.2%
89.8%

Abnormal vaginal bleeding (Reported)
Abnormal vaginal bleeding (Not
reported)

720
270

72.7%
27.3%

Density per km2
Travel distance
HIV prevalence
Individual Level Factors
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Figure 3. 1. Age- standardized presentation rates per sub-district referred to MDT clinic in

Gaborone, Botswana

Central
Kalahari
Game
Reserve
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Table 3.2. Crude and age standardized presentation rates per 100,000 women
Total
Cases

Sub-district
CENTRAL KGALAGADI GAME RESERVE
NGAMILAND DELTA
SOWA TOWN
NGAMILAND WEST
GHANZI
KGALAGADI NORTH
SELIBE PHIKWE
TUTUME
NGAMILAND EAST
NORTH EAST
BOTETI
ORAPA
SOUTH EAST
GABORONE
SEROWE PALAPYE
KWENENG EAST
BOBONONG
KGALAGADI SOUTH
BAROLONG
CHOBE
JWANENG
KWENENG WEST
LOBATSE
MAHALAPYE
KGATLENG
SOUTHERN
FRANCISTOWN
NGWAKETSE WEST
TOTAL

0
0
0
10
7
3
9
39
20
19
15
2
40
105
95
142
36
16
31
14
6
28
14
75
75
102
66
21
990
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Population
(age 20+)
138
5,399
5,204
96,743
70,513
33,166
76,875
248,989
154,106
107,059
91,761
15,783
187,109
391,426
205,953
517,133
113,269
49,078
88,936
45,030
30,305
74,313
47,665
187,537
172,897
217,937
184,808
23,062
3,635,573

Crude
rate per
100,000
0
0
0
9.30
9.93
10.33
11.71
15.66
12.98
17.75
16.35
12.67
21.38
26.83
31.05
27.46
31.78
32.6
34.86
31.09
19.8
37.68
29.37
39.99
43.38
46.8
35.17
91.06
27.23

Agestandardi
zed rate
per
100,000
0
0
0
9.49
10.62
9.16
11.37
13.51
13.75
16.07
16.48
19.56
22.67
27.07
28.07
29.42
29.55
29.76
30.91
34.25
34.5
35.37
35.76
35.94
39.87
41.16
45.85
75.98
27.23

Table 3.3. Community level factors for identified HH and LL sub-districts
Community level factors

HH sub-districts

Standard
Deviation

LL Sub-districts

Standard
Deviation

Number of sub-districts
Number of cases
presentation rates (mean)

3
37
35.5

--7.78

2
118
11.33

--2.52

Population density per km2
Travel distance
HIV prevalence

8.82
341.5
11.45

11.25
255.27
0.49

1.94
912.0
15.27

0.93
274.97
1.8

Figure 3. 2. Identified High-High and Low-Low clusters of presentation rates
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Table 3.4. Results of OLS regression with spatial weights matrix for community level
factors
OLS regression

Coef

prop

aCoef*

prop

HIV

0.059

0.940

-0.084

0.912

Density

1.75

0.560

-3.044

0.406

Travel distance

-0.020

0.034

-0.026

0.033

*adjusted coefficients

Table 3. 5. Univariate analysis of Individual level factors for patients presenting from
identified HH and LL sub-districts
Individual Level Factors

Patients
living in an
LL Subdistrict

Patients not
living in an
LL subdistrict

Sample Size(n)
Age (mean (range))

37
47.4
(29.0-73.5)

953
50.7
(22.4-95.2)

Patients living
in an HH subdistrict

Patients not
living in an
HH subdistrict

118
53.4
(31.0-89.4)

872
50.2
(22.4-95.2)

N (%)

N (%)

N (%)

N (%)

32 (86.5%)
5 (13.5%)

648 (69.2%)
288 (30.8%)

0.025

64 (55.7%)
51 (44.3%)

616 (71.8%)
242 (28.2%)

<0.001

Marital Status
Married/widowed/divorced
Never married/single

14 (37.8%)
23 (62.2%)

325 (34.1%)
628 (65.9%)

0.640

43 (36.4%)
75 (63.6%)

296 (33.9%)
576 (66.1%)

0.590

FIGO stage at diagnosis
Early Stage (stage I/II)
Late Stage (stage III/IV)

18 (52.9%)
16 (47.1%)

472 (53.9%)
404 (46.1%)

0.910

47 (42.3%)
64 (57.7%)

443 (55.4%)
356 (44.6%)

0.009

Cervical cancer screening
Ever
Never

21 (61.8%)
13 (38.2%)

525 (57.6%)
387 (42.4%)

0.630

66 (59.5%)
45 (40.5%)

480 (57.5%)
355 (42.5%)

0.690

Visit with a traditional healer
Ever
Never

3 (8.3%)
33 (91.7%)

95 (10.2%)
834 (89.9%)

0.710

12 (10.3%)
104 (89.7%)

86 (10.1%)
760 (89.9%)

0.940

Abnormal vaginal bleeding
Reported
Not reported

34 (91.9%)
3 (8.1%)

686 (72.0%)
267 (28.0%)

0.008

89 (75.4%)
29 (24.6%)

631 (72.4%)
241 (27.6%)

0.48

HIV status
Living with HIV
Living without HIV
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pvalue

0.12

pvalue

0.010

Table 3.6. Multivariable regression for individual level factors associated with patients
living in sub-districts with disproportionate rates
aOR

95% CI

p-value

LL sub-districts

aOR

95% CI

p-value

HH sub-districts

Age

1.00

0.96-1.03

0.798

1.00

0.98-1.02

0.956

HIV
(Living with vs. without)
Never married/single vs.
married/widowed/divorced

3.29

0.97-11.17

0.057

0.46

0.27-0.78

0.004*

0.50

0.23-1.08

0.077

0.98

0.61-1.56

0.918

FIGO stage
(stage III/IV vs. I/II)

0.95

0.46-1.99

0.898

1.85

1.19-2.87

0.006*

Cervical cancer screening
(Ever vs. never screened)

1.03

0.48-2.21

0.930

1.31

0.84-2.05

0.229

Visit with a traditional
healer (Ever/never)

0.88

0.26-2.98

0.832

1.24

0.73-2.12

0.906

5.88

1.37-25.23

0.017*

1.24

0.73-2.12

0.422

Abnormal vaginal bleeding
Reported vs. Not reported
aOR: adjusted Odds ratio
95% CI: 95% Confidence Interval
*p<0.05
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CHAPTER 4. Stage at cervical cancer presentation and distance to MDT clinic in
Gaborone for women living with and without HIV infection in Botswana

4.1. Abstract

4.1.1. Background

Cervical cancer is the leading cause of cancer death for women in Botswana. Later
stage at presentation and barriers to access are associated with increased cancer
mortality in low resource settings. Reduced access to the only gynecological cancer
multi-disciplinary team (MDT) clinic from a woman’s residence may be associated with
later stage of cervical cancer. Additionally, with a high prevalence of women living with
HIV in Botswana, HIV status may also be associated with access to care.

4.1.2. Methods
We included cervical cancer cases presenting to the MDT clinic for staging and
treatment between 2015 and 2020. Multinomial adjusted logistic regression was used to
examine the association of stage at presentation and travel time from residence to the
MDT clinic. Multivariable logistic regression was also used to evaluate the association of
HIV status and travel time.

4.1.3. Results
We identified 959 cervical cancer patients. Mean age at diagnosis was 50.7 (range: 2295). The majority of cancers were stage II (35.9%) and stage III (37.7%) at presentation,
median travel time to clinic was 124 minutes, and 70.1% were living with HIV.
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Increasing travel time was associated with later stage of cervical cancer at presentation.
When compared to the reference group of stage I disease and a travel time within one
hour to the MDT clinic, the odds of a presenting with stage II were doubled for patients
traveling 3-5 hours (OR: 2.00, 95% CI 1.14-3.52) and over two-times greater for patients
traveling over 5 hours (OR: 2.19, 95% CI: 1.15-4.19); the odds of stage IV was almost
three times greater when traveling 3-5 hours (OR: 2.93, 95% CI 1.26-6.79) and four
times greater traveling over 5 hours (OR: 4.05, 95% CI: 1.62-10.10). Logistic regression
also found the odds of a patient living with HIV was increased with increasing travel time
to the MDT clinic (trend test p-value=0.004).
4.1.4. Conclusions
We found that increasing travel time from residence to the MDT clinic, and living with
HIV, were associated with later stage of cervical cancer at presentation. An
understanding of interventions to remove distance related barriers to care may help
improve early diagnosis and reduce mortality for cervical cancer patients in Botswana.
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4.2. Introduction

Cervical cancer is highly preventable and treatable if detected early. In Botswana,
cervical cancer is the most common cause of cancer death among women (1, 2) and is
an acquired immunodeficiency syndrome (AIDS) -defining malignancy. Botswana has a
high human immunodeficiency virus (HIV) prevalence: over 25% of females between 1549 years live with HIV (3), and almost 70% of women diagnosed with invasive cervical
cancer live with HIV (4, 5). Due to advances in HIV care, the population of Botswana is
living longer, which has resulted in rising morbidity and mortality from AIDS related
cancers including cervical cancer. The Botswana Ministry of Health and Wellness
(MOHW) has partnered with the President’s Emergency Plan for AIDS Relief (PEPFAR)
and The Johns Hopkins Program for International Education in Gynecology and
Obstetrics (JHPIEGO) to curb the cervical cancer disease burden primarily in women
living with HIV (WLWH) (6, 7). The MOHW has also adapted the American Society of
Clinical Oncology (ASCO) resource limited stratified screening strategies for all its
citizens (8, 9). ASCO’s secondary prevention for cervical cancer in limited resource
settings consists of screening with HPV DNA testing for women 30 to 49 years of age
every 10 years, corresponding to two to three times per lifetime (10).

Botswana has a population of approximately 2.3 million and has government funded
healthcare, ensuring affordable healthcare for all citizens, including cervical cancer
screening and cancer treatment (11). The de-centralized health care system ranges from
health posts to referral hospitals (12). Health posts are staffed with a health education
assistant, a lay counselor, a nurse and occasionally a midwife or a doctor. Clinics offer
mainly primary health care and outpatient services, including offering various modes of
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screening or testing for cervical cancer. Hospitals are defined by three tiers: district,
primary and referral hospitals. Referral hospitals are the only facilities capable of treating
specialized diseases like cancer (13). There is one referral hospital is in Francistown:
Nyangabgwe Referral Hospital (NRH), and two referral hospitals located in the capital
city of Gaborone: Princess Marina Hospital (PMH) and Gaborone Private Hospital
(GPH). In 2015 a multidisciplinary gynecological oncology team (MDT) was formed at
PMH to provide comprehensive care for all gynecological cancer patients in Botswana
(14). The MDT clinic coordinates care for all cervical cancer patients referred from health
facilities around Botswana and has a highly specialized team and equipment, including
the only gynecological oncologist in the country and the only chemoradiotherapy facility
capable of treating patients with locally invasive cancer (15-17).
With limited resources, it is a challenge for all women in Botswana to have equitable
access to specialized cancer care. A critical factor that affects cancer outcomes is
cancer stage. Later stage cervical cancers have higher mortality rates (5, 18). Studies in
Botswana have shown that access to care can influence stage at diagnosis, as a delay
in presentation can result in progression of a malignant tumor to a late stage (19-21).
One aspect of access to care, accessibility, which can be measured in travel-time, has
been associated with a delay in cancer presentation and subsequently late-stage
outcomes (22, 23). Travel time and its impact on stage of cervical cancer patients
presenting for treatment and care in Botswana has yet to be explored.
This study aimed to describe the travel burden for patients with cervical cancer
presenting to the comprehensive MDT cancer clinic in Gaborone. We examine stage of
cervical cancer at presentation as influenced by travel time from the patient’s residence
to the MDT clinic. We hypothesized that patients with a greater travel time from their
residential village to the MDT clinic in Gaborone, would be more likely to present with
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late-stage disease than patients with shorter travel time to the MDT clinic. We also
examine HIV status among patients according to their travel time to health care facilities.
We hypothesized that HIV status may influence inequity in accessing cervical cancer
care, in that WLWH would be more likely to present for care from more remote villages
than patients without HIV.

4.3. Methods

4.3.1. Study population

This study, describe previously, included cervical cancer patients presenting to the MDT
clinic for cervical cancer staging and treatment in the capital city of Gaborone between
January 2015 and March 2020(14, 24). Eligible patients were over the age of 18, not
pregnant, and were not diagnosed with cervical carcinoma in situ or had recurrent
disease.

4.3.2. Abstracted data

4.3.2.1. Geographic data
The residential village for each patient was abstracted from the questionnaire
administered at the initial consult visit at the MDT clinic. Using the United States Census
Bureau’s (USCB) geographic shapefile that included 519 village polygons in Botswana
(25), patients were linked to their respective village and geocoded using ARCGIS to the
geographic centroid of their village. Latitude and longitude coordinates for each village
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centroid were obtained from the ARCGIS geography feature(26). We also abstracted the
facility patients reported being referred from and geocoded these facilities using the
latitude and longitude coordinates from the Botswana health facilities list provided Maina
et al. (2). PMH coordinates were used for the MDT clinic.
We also calculated rates of presentation (henceforth referred to as ‘presentation rates’)
of cervical cancer cases for each village. We defined presentation rates for each village
as the number of patients with cervical cancer presenting to the MDT clinic from each
village (as the numerator) divided by the total number of women village at risk for each
village abstracted from the US census average annual population projection for females
20 years and older (25) (as the denominator).
The main metric of access, geographic proximity of village of residence to the MDT
clinic, was measured using travel time. In google maps (27) using the geographic
coordinates of the village centroid as the starting point, we imputed the travel time in
minutes to the MDT clinic at PMH in Gaborone for each patient (28). Travel time was
calculated using road networks and travel routes as available in google maps.

4.3.2.2. Travel time from village to MDT clinic

Travel time to the MDT clinic in Gaborone was measured in minutes and categorized in
hours. Using the mean travel time of approximately 3 hours as the midpoint, we
characterized travel time into four categories: < 1 hour (11-59 minutes), 1-3 hours (60179 minutes), 3-5 hours (180-299 minutes), 5+ hours (>300 minutes). Travel time was
mapped and displayed using a choropleth map using ARCGIS (26). We additionally
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measured the travel burden using 1) straight line Euclidian distance using ARCGIS (26)
and 2) driving distance in kilometers from google maps (28).

4.3.2.3. Clinical Outcomes

The primary outcome of interest was stage of cervical cancer at presentation based on
the International Federation of Gynecology and Obstetrics (FIGO) staging system (18,
29), and was categorized as stage I (IA, IA1, IA2, IB, IB1, IB2, IB3), stage II (IIA, IIB),
stage III (IIIA, IIIB, IIIC), and stage IV (IVA, IVB). Current standard of care for patients
with locally advanced cervical cancer (stages IB2 -IVA) is definitive chemoradiotherapy
(18, 30).

Secondary outcome of HIV status was dichotomized to WLWH and women without HIV
based on clinical abstraction of the patient’s medical records at the time of the initial
MDT clinic visit.

4.3.2.4. Social-demographic and clinical variables
Data were abstracted from questionnaires administered during the initial consult visit and
from medical records. Data collected at the time of cancer presentation included patient
sociodemographic and clinical factors (i.e., address (village), age, marital status, place of
residence, history of cervical cancer screening, ever/never visit with a traditional doctor
and/or natural healer, presence of abnormal vaginal bleeding (including post-coital
bleeding/bleeding after vaginal intercourse), and HIV status). We also collected type of
referral facility as reported in the questionnaire (health post, clinic, or hospital) (2).
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Residence was characterized as urban or rural based on the village of the patient’s geocoded residence (11).

We also obtained the female HIV prevalence for each village using the estimates
provided for the sub-district for each village in the Botswana AIDS Impact Survey
IV((31).

4.3.3. Statistical Analysis

Descriptive statistics are presented for the entire study sample. We also examined
variables of interest by travel time from village residence to the MDT clinic using
Pearson’s chi-squares test for categorical variables, student t-tests and ANOVA for
continuous variables as appropriate. Variables of interest were determined a priori based
on availability, purposeful selection, review of the literature, and clinical relevance. The
explanatory variable of interest was travel time from village residence to the MDT clinic
in Gaborone.

We used multinomial (polytomous) logistic regression to estimate the odds ratios for
each stage of cervical cancer at presentation (stage II, III, and IV) compared with the
reference stage, stage I, by travel time to MDT clinic. We ran univariate and
multivariable regression models adjusted for potential confounders as previously
described (24). Variables included age, marital status, history of cervical cancer
screening, ever/never visit with a traditional healer, presence of abnormal vaginal
bleeding, and urban versus rural residence. We also investigated the interaction of travel
time with HIV status with respect to stage at presentation.
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Logistic regression models, both unadjusted and adjusted for a priori selected variables:
age, marital status, history of cervical cancer screening, ever/never visit with a traditional
healer, urban versus rural residence, and presence of abnormal vaginal bleeding, were
used to assess any association of living with HIV and different levels of access defined
by travel time categories to clinical care at the MDT clinic.

All statistical analyses were conducted using STATA 16. Odds ratios (OR) and 95%
confidence intervals (CIs) were reported. All tests were two-sided and p-values <0.05
were considered statistically significant.

4.3.1.5. Sensitivity Analysis

Our main analysis was a complete case analysis, but we also conducted a sensitivity
analysis to account for missing data in our confounding variables. We used multiple
imputation with chained equations (MICE) assuming data were missing at random (3234) and conducted separate logistic regression models to compare each stage (stage IIIV) separately to stage I. Amounts of missingness were assessed and were mostly
minimal except for health facility referred from (health post, clinic or hospital) which had
over 20% missing data. Health facility was not included in the main complete case
analysis, but we imputed health facility in the MICE analysis to allow us to assess any
potential confounding effect of health facility.

4.4. Results
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4.4.1. Patient Characteristics

Between January 2015 and March 2020, 1,019 patients presented to the MDT clinic with
cervical cancer. Nineteen patients (1.8%) were diagnosed with cervical carcinoma in situ
and 7 (0.7%) patients with recurrent disease were excluded. Thirty-four patients (3.3%)
were missing village of residence. Sociodemographic and clinical characteristics of the
959 eligible patients are shown in Table 4.1. Almost eighteen percent (n=157) of patients
presented with stage I cervical cancer, 35.9% (n=316) with stage II, 37.7% (n=332) with
stage III and 8.6% (n=76) with stage IV. Locally invasive cervical cancer is defined by
cancer confined to the cervix and is FIGO stage IB2 or later; 88.6% (n=832) patients had
stage IB2 or later. Our sample included 70.1% (n=660) of WLWH with mean age at
presentation of 50.7 years (range: 22.4-95.2). The majority of patients 65.5% (n=628)
had never been married, 57.6% (n= 530) reported previous cervical cancer screening,
abnormal vaginal bleeding was reported in 72.7% (n=697) of patients, 10.3% (n=96)
reported ever having a visited with a traditional healer and 21.7% (n=208) lived in urban
areas. Median travel time from their residence to the MDT was 124.0 minutes (IQR:
54.0-280.0) and median distance was 134.4 km (IQR: 52.8-392.9). Over half of the
patients (53.8%; n=516) were referred from a clinic, 17.2% (n=165) from a health post,
and 11.3% (n=108) from a hospital. Almost 18% percent (n=170) of patients did not
report having been referred from a health facility.

4.4.2. Patient characteristics by travel time from village of residence to MDT clinic

Patient characteristics by travel time from village of residence to MDT clinic are
presented in Table 4.2. Travel time to MDT clinic throughout Botswana is visually
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presented in Figure 1. Thirty two percent of cervical cancer patients (n=309) traveled
less than one hour from their village of residence to the MDT clinic, 25.5% (n=245)
traveled 1-3 hours, 25.3% (n=243) traveled 3-5 hours, and 16.9% (n=162) traveled more
than 5 hours. Across these groups, patients differed in stage at presentation (p=0.016),
HIV status (p<0.001), age (p=0.012), urban residence (p<0.001), and type of referral
facility visited (p<0.001).

4.4.3. Presentation rates by travel time from village of residence to MDT clinic

Presentation rates for cervical cancer patients (the number of patients presenting for
treatment out of the number of women in the village at risk) for each travel time category
are shown in Figure 4.2. Rates of cervical cancer cases presenting to the MDT clinic
declined with increasing time to clinic. Rates were the highest for patients traveling 1-3
hours to the MDT clinic (39.1 per 100,000 women) and lowest for patients traveling more
than five hours (17.5 per 100,000).

4.4.4. Association of travel time from village to MDT clinic and cervical cancer stage at
presentation

The odds of presenting with a later stage cancer increased with travel time to MDT clinic
from village of residence (Table 4.3). In the multinomial regression model, the odds of
presenting with stage II versus stage I cancer were doubled (OR: 2.01, 95% CI 1.143.52) for patients traveling 3-5 hours and more than two-fold when traveling over five
hours (OR: 2.18, 95% CI: 1.10-4.31) compared to traveling less than one hour. Also,
there was a significant trend for increasing odds of stage II versus stage I with increased
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travel time (p<0.001). For stage III cancers versus stage I, there were no significant
associations by travel time. The odds of presenting with stage IV cancer versus stage I
cancer was almost three times greater when traveling 3-5 hours (OR: 2.97, 95% CI 1.286.90) and increased four-fold for patients traveling over five hours (OR: 4.26, 95% CI:
1.61-11.30) compared to traveling less than one hour (trend test p<0.001). We did not
find a significant interaction between travel time and HIV status with respect to stage at
diagnosis (p=0.155).

4.4.5. Proportion of cervical cancer cases by HIV status presenting to the MDT clinic

The proportion of cervical cancer cases by HIV status presenting to the MDT clinic
differed with increasing travel time to MDT clinic (Figure 4.3). Proportion of WLWH was
the lowest for patients traveling 1-3 hours to the MDT clinic (59.8%) and highest for
patients traveling more than five hours (78.6%). The average HIV female prevalence for
each village using the estimates provided in the Botswana AIDS Impact Survey IV((31)
was analogous across all time categories (range: 19.7-21.1).

4.4.6. Association of travel time to MDT clinic and HIV status
A significant trend was observed in the adjusted analysis showing increasing odds of
living with HIV for patients with increasing travel times to the MDT clinic (p=0.002) (Table
4). Patients living over five hours away were twice as likely to be WLWH as patients
traveling <1 hour (aOR: 2.03, 95% CI: 1.10-3.75).

4.4.7. Sensitivity analysis
Results for the MICE analysis for the main model were similar in magnitude and
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direction to what is presented in the main analysis. For the MICE analysis including
referral facility type, the results were similar and magnitude and direction, thus imputing
referral facility did not alter the results.

4.5. Discussion

This study delineates the travel time for cervical cancer patients from their village of
residence to the comprehensive MDT cancer clinic at PMH in Gaborone, Botswana.
Approximately 50% of patients traveled over 3 hours and more than 200 km to the MDT
clinic. We found that patients had an increased odds of presenting with later stage
disease with increased travel time. We also found that the presentation rates differed
according travel times, with the highest presentation rate for patients traveling 1-3 hours
to the MDT clinic and lowest for patients traveling more than five hours. Given that we
observed only very slight differences in underlying female HIV prevalence among
different travel times categories supports the inference that the difference in presentation
rates may not be due to biology or incidence but due to access, as patients who develop
cervical cancer may not be presenting for staging and care. Travel time was also
associated with a patient’s HIV status. Patients with greater travel time to the MDT clinic
were more likely to be living with HIV, suggesting that HIV status may increase the
likelihood of presenting for cervical cancer care.

4.5.1. Association of travel time to MDT and late-stage cervical cancer

Many studies in high income countries and in LMICs have found an increased travel
burden to be a risk factor for poor health outcomes, including late stage at cancer
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presentation (22, 23, 35). The literature has reported access to care as an important
factor for cancer survival, including in LMICs (36-38). Two studies in sub-Saharan Africa
(SSA) showed that greater distance to diagnostic/treatment facility was associated with
an increased odds of late-stage breast cancer (23, 35). A systematic review of over 108
studies investigating the effect of distance and health outcomes reported that most
studies (77%) reported further distances having poorer health outcomes (eg, lower
survival rates), a few (6%) found further distances to be associated with improved health
outcomes, and some (17%) found no relationship between distance and outcomes (22),
though the studies of null findings could be underestimated due to lack of reporting nonsignificant results. Our study found that increased travel time to the MDT clinic increased
the odds of presenting with poorer outcomes defined here as later stages of cervical
cancer.

Later stage at presentation is likely a result of multiple patient level and health system
delays that are exacerbated at further distances. Travel time is one aspect of access to
care, but multiple factors impact access. As noted by Penchansky and Thomas(39),
access is multi-dimensional and consists of availability, accessibility, accommodation,
affordability, and acceptability. Availability depends on adequate services and health
care providers for the patient population it is servicing. Accessibility is measured in travel
time and distance (as we did), but type of transportation and costs related to
transportation also need to be considered. Accommodation describes the ability to see
patients when they need to be seen, as well as communication between health care
providers and patients. Affordability involves the financial burden as well as the
individual’s perception of the costs being justifiable and necessary. Acceptability takes
into account attitudes, knowledge, awareness and beliefs about personal and practice
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characteristics of the providers and services, as well as the providers’ perception of the
service as it relates to the patient(39). Living further away from comprehensive cancer
care in a resource limited setting is vulnerable to all of these aspects of access.

A recent review of 15 studies in LMICs(40) reported that lack of knowledge related to
cervical cancer and cervical cancer screening to be the most prevalent barrier to cervical
cancer screening. Awareness and understanding of the importance and benefits for
screening for cervical cancer are imperative to improve cervical cancer outcomes. Two
studies in Botswana (41, 42) reported that the lack of understanding of risk factors for
cervical cancer and lack of understanding the importance and benefits of cervical cancer
screening were barriers to accessing cervical cancer screening. Zapka and Taplin et al
(43) note in their Quality in the Continuum of Cancer Care framework ‘failure to identify
the need to screen and counsel’ as the first potential failure during the processes of
cancer care. This could be particularly true for women living further away from treatment
facilities in more rural and remote areas of the country. In these areas, women and
health care providers may be unaware of the need to screen for cervical cancer and may
lack knowledge regarding the symptoms related to cervical cancer. These burdens for
areas further away, together with the cost and feasibility of travel, are all likely
contributing to barriers in access and more advanced stage disease at presentation.
Future work should stress the importance of provider and patient education to address
some of these barriers so that people who are at a distance are more willing to assume
the cost/time of travel to a specialty care center.

4.5.2. Presentation rates of cervical cancer patients presenting to MDT
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We also noted that the rate of cervical cancer patients presenting to the MDT clinic
differed by travel times across the country. Areas where rates are lower could indicate
that not all cervical cancer patients are presenting for appropriate care and treatment.
Rates of women presenting for care were not linear in relation to travel time. Rates were
the highest 1-3 hours from Gaborone. Rates were lower within a travel time of one hour
and a travel time of more than five hours to the MDT clinic. These differences in rates
area likely a reflection of several inadequate aspects related to access. Urban areas like
Gaborone are less susceptible to distance delays, but urban areas tend to have lower
socioeconomic status (SES) which has been linked to poorer health outcomes and
decreased survival for cancer (44). However, with lower income populations in urban
areas, the travel cost (i.e., public transportation), the burden of childcare, and lost wages
due to missing work are just some of the additional factors that can contribute to the
inability to access care. In densely populated urban areas there can also be low
availability, particularly a disproportionate supply and demand for health services which
can contribute to less patients presenting for care.

Areas beyond five hours away with low rates are also likely impacted by multilevel
barriers to access including availability and accessibility to health services, as mentioned
above. In Botswana, Gaborone and Francistown are considered the two main urban
areas while the rest of the country is sparsely populated and largely rural. Further
distances tend to be even more remote with population density of less than 1 person per
km2. As described by Iyer et al (45), population density is inversely associated travel
time in four SSA countries. Additionally, studies in SSA have noted more advanced
disease in rural patients compared to urban patients (46, 47). In Botswana, remote, rural
areas over 5 hours away from Gaborone may have less cervical cancer awareness
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campaigns, less cancer related services, and fewer providers capable of providing care
for cancer patients. These burdens, together with the cost and feasibility of travel, all
contribute to fewer patients presenting for care and delays in access contributing to
more late-stage disease at presentation.

4.5.3. Travel time and HIV status

Our results also show that the proportion of patients living with HIV increased with
increasing distance from the MDT clinic. Given that the prevalence of WLWH was quite
similar by travel time categories(31), we wouldn’t expect that risk factors for HPV/HIV
infection to differ drastically across locations, and therefore we do not expect the
differences in rates to be driven by underlying risk differences or difference in incidence.
Instead, our results may give us insight into the influence HIV status may have when
presenting for care. In the wake of the HIV epidemic, several steps have been taken to
prioritize cervical cancer prevention, particularly in WLWH, who are 4-6 times more likely
to develop cervical cancer than women without HIV (48). Collaborating with the
President’s Emergency Plan for AIDS Relief (PEPFAR) (19), the MOHW established
national cervical cancer prevention services (17). Understanding that these programs
have been initiated targeting high-risk WLWH, women without HIV may have different
experiences with cervical cancer screening. These differences could include individual
level factors such as awareness of the benefits or the availability of cervical cancer
screening, as well as health system level effects, where providers recognize cervical
cancer screening as beneficial for high risk WLWH but not in women without HIV.
Additionally, over 80% of people living with HIV in Botswana are on anti-retroviral
therapy as appropriate (31), and thus have regular contact with healthcare providers and
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facilities. This increased interaction could provide WLWH with more educational
resources and more opportunities to test or screen for cervical cancer than women
without HIV (49). Thus, women without HIV likely have decreased awareness,
knowledge, resources, and opportunities regarding cervical cancer and cancer screening
and may not be referred to diagnostic/treatment facilities in Gaborone to the same extent
as WLWH. This phenomenon was also hypothesized in a previous study in Botswana
investigating delays in cancer care (49). Thus, without appropriate awareness and
knowledge, women and health care providers may fail to identify the need to screen and
treat all women at risk for cervical cancer. This could be particularly challenging for
patients without HIV and living further away from treatment facilities, and a hypothesis
supported by our findings of less patients without HIV from further distances presenting
to the MDT clinic.

4.5.4. Strengths and weaknesses

This study investigating later stage of cervical cancer at presentation to an MDT clinic in
Botswana includes almost one thousand cervical cancer patients, but it does have
several potential limitations and challenges. Due to the cross-sectional study design, no
conclusions can be made about causality of the study variables on late stage at
presentation. Here we are using travel-time to generate hypothesis aimed at
understanding geographic differences in late-stage diagnosis. Caniglia et al (50)
described methodological challenges when using distance to care as an exposure for
health outcomes and identified selection bias as an influencing factor affecting the
relationship. While our study is vulnerable to selection bias, the degree of selection bias
in our study cannot be accurately quantified due to the lack of a reliable population
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based cancer registry indicating the known incidence and/or prevalence of cervical
cancer (1). While we were unable to account for patients who did not present to the MDT
clinic, our results do give us valuable insight into differences between those presenting
and not presenting for treatment, specifically selection bias by travel time and HIV
status. There is also the possibility of selection bias by disease stage, as some cervical
cancers, particularly stages earlier than locally advanced disease (stage< IB2), may be
treated with surgical procedures outside of Gaborone or even outside of Botswana and
not get referred for further treatment. For example, cervical cancer patients living closer
to Francistown may present to the tertiary hospital NRH. Early-stage patients presenting
to NRH may be treated with surgery and/or chemotherapy, and thus our results would
have an underrepresentation of cervical cancers in this area. Additionally, if a
radiotherapy facility is not needed for treatment with curable intent for patients with stage
IV disease, these patients may also not be referred to Gaborone. However, all patients
with locally advanced invasive disease (stage IB2-IVA) should be referred to MDT for
appropriate standard of care treatment with radiotherapy. Of note, our sample did
include 65 patients from Francistown, 12.3% presenting with earlier than stage IB2
disease. This is consistent with the overall presenting rate earlier than stage IB2 in our
sample (11.4%). Our results showed that the proportion of cancers with stages less than
locally advanced disease did not significantly differ across the travel time categories,
suggesting that our findings are unlikely to be fully explained by selection bias. Though
selection bias is a potential issue in estimating associations of exposures with cervical
cancer outcomes in this study, identifying potential selection bias in this study is an
important finding in itself, as it can help identify women that are not being “selected” or
presenting for the appropriate cervical cancer treatment in Botswana.
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To account for bias in our study due to missing data, we conducted MICE for sensitivity
analysis (32-34). Results using MICE were similar to the complete case analysis. In
addition, the study collected data at the time of presentation and is therefore subject to
recall bias, social desirability bias, and potential unmeasured confounding. Caniglia et al
(50) also described unmeasured confounding as a potential bias for studies investigating
distance to care. Unfortunately, due to the retrospective nature of the study, we lacked
important information and were unable to account for confounders including
socioeconomic status, education level, knowledge, and awareness of cervical cancer
and cervical cancer screening, although we were able to account urban and rural status
which could be a proxy for some of these factors. Lastly, it is possible that there is some
degree of misclassification of the travel time designation due to the centroid of the village
being used and not a specific address. However, we don’t expect this as a major source
of bias as choosing the centroid of the village is a more systematic way to determine a
location than any random point in the village and we would not expect this bias to be
differential in any way.

As mentioned, this study examined only on metric of access, travel time, it will be
important for future studies to investigate additional aspects of access. Untangling
differences in awareness, knowledge, screening, and health systems factors along the
cervical cancer care continuum will offer insight into areas where future interventions
would be most effective and beneficial.

4.5.4. Conclusion
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Increasing travel time is associated with later stage cervical cancer at presentation to the
MDT clinic for treatment. Additionally, the proportion of WLWH also increases with
increasing travel time to the MDT clinic, suggesting that HIV status may be influencing
inequity in presenting for cervical cancer care. This study highlights the importance of
investigating barriers to accessing advanced cancer care and identifying modifiable
factors that influence inequitable access to appropriate treatment to improve cervical
cancer outcomes for all women in Botswana.
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Table 4.1. Characteristics of the study population
CHARACTERISTICS
TOTAL

CATEGORIES

TOTAL
N=959

STAGE OF CERVICAL CANCER

I
II
III
IV
< Stage IB2
> Stage IB2

157 (17.8%)
316 (35.9%)
332 (37.7%)
76 ( 8.6%)
107 (11.4%)
832 (88.6%)

Women without HIV
WLWH*
mean (range)
2015
2016
2017
2018
2019
2020
Ever married
Never married
Never
Ever
Not reported
Reported
Never
Ever
Rural
Urban
median (IQR)
median (IQR)
Clinic
Health Post
Hospital
Unknown

282 (29.9%)
660 (70.1%)
50.7 (22.4-95.2)
95 ( 9.9%)
169 (17.6%)
240 (25.0%)
199 (22.3%)
218 (22.0%)
42 ( 4.4%)
331 (34.5%)
628 (65.5%)
390 (42.4%)
530 (57.6%)
262 (27.3%)
697 (72.7%)
839 (89.7%)
96 (10.3%)
750 (78.3%)
208 (21.7%)
124.0 (54.1-280.0)
2.4 (65.4-443.8)
516 (53.8%)
165 (17.2%)
108 (11.3%)
170 (17.7%)

LOCALLY ADVANCED CERVICAL CANCER
HIV STATUS
AGE IN YEARS
YEAR PRESENTED AT MDT

MARITAL STATUS
EVER CERVICAL CANCER SCREENING/TESTING
REPORT OF ABNORMAL VAGINAL BLEEDING
EVER VISIT WITH A TRADITIONAL HEALER
URBAN/RURAL RESIDENCE
TRAVEL TIME TO MDT IN MINUTES
TRAVEL DISTANCE TO MDT IN KILOMETERS
REFERRAL FACILITY

*WLWH: women living with HIV
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Figure 4. 1. Distribution of travel time from the MDT clinic in Gaborone
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Table 4.2. Characteristics of the study population by travel time

TOTAL
STAGE OF CERVICAL
CANCER
LOCALLY ADVANCED
CERVICAL CANCER

HIV STATUS

AGE IN YEARS
MARITAL STATUS

CERVICAL CANCER
SCREENING/TESTING
ABNORMAL VAGINAL
BLEEDING
VISIT WITH A
TRADITIONAL
HEALER
URBAN/RURAL
RESIDENCE
TRAVEL TIME TO
MDT IN MINUTES
TRAVEL DISTANCE
TO MDT IN
KILOMETERS
REFERRAL FACILITY

pvalue

< 1 HOUR
N=309
60 (21.3%)
96 (34.0%)
111 (39.4%)
15 (5.3%)

1-3 HOURS
N=245
48 (20.8%)
71 (30.7%)
93 (40.3%)
19 (8.2%)

3-5 HOURS
N=243
31 (14.4%)
88 (40.7%)
72 (33.3%)
25 (11.6%)

5+ HOURS
N=162
18 (11.8%)
61 (40.1%)
56 (36.8%)
17 (11.2%)

35 (11.6%)
267 (88.4%)

36 (17.9%)
206 (85.1%)

21 (8.9%)
214 (91.1%)

15 (9.4%)
145 (90.6%)

0.170

84 (27.9%)

97 (40.2%)

67 (27.8%)

34 (21.4%)

<0.001

217 (72.1%)
50.0 (27.584.4)
106 (34.3%)

144 (59.8%)
52.9 (27.786.8)
84 (34.3%)

174 (72.2%)
49.8 (22.495.2)
85 (35.0%)

125 (78.6%)
50.2 (22.681.2)
56 (34.6%)

203 (65.7%)

161 (65.7%)

158 (65.0%)

106 (65.4%)

131 (43.7%)

103 (43.6%)

96 (41.6%)

60 (39.2%)

0.79

Ever
Not
reported
Reported
Never

169 (56.3%)
84 (27.2%)

133 (56.4%)
72 (29.4%)

135 (58.4%)
65 (26.7%)

93 (60.8%)
41 (25.3%)

0.83

225 (72.8%)
273 (89.5%)

173 (70.6%)
208 (86.7%)

178 (73.3%)
209 (90.5%)

121 (74.7%)
149 (93.7%)

0.15

Ever
Rural

32 (10.5%)
190 (61.7%)

32 (13.3%)
235 (95.9%)

22 ( 9.5%)
164 (67.5%)

10 ( 6.3%)
161 (99.4%)

<0.001

Urban
median
(IQR)

118 (38.3%)
39.1 (11.954.1)

10 ( 4.1%)
98.3 (87.0124.9)

79 (32.5%)
252.6 (219.1298.7)

median
(IQR)

35.6 (8.252.8)

106.4 (90.5151.1)

375.5 (296.5439.7)

I
II
III
IV
< Stage
IB2
> Stage
IB2
Women
without
HIV
WLWH*
mean
(range)
Ever
married
Never
married
Never

Clinic
Health
Post
Hospital
Unknown

176 (57.0%)
43 (13.9%)

134 (54.7%)
45 (18.4%)

148 (60.9%)
35 (14.4%)

1 ( 0.6%)
389.7
(348.2560.8)
532.3
(485.8842.8)
58 (35.8%)
42 (25.9%)

41 (13.3%)
49 (15.9%)

18 ( 7.3%)
48 (19.6%)

24 ( 9.9%)
36 (14.8%)

25 (15.4%)
37 (22.8%)
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0.016

0.020
1.00

<0.001
<0.001
<0.001

Figure 4. 2. Cervical cancer rates per 100,000 among women age 20+ presenting to the
MDT clinic
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Table 4. 3. Multinomial logistic regression for travel time and stage at presentation
cOR*
STAGE I
STAGE II
<1 HR
1-3 HRS

95% CI

unadjusted
ref
ref

0.92
1.77

5+ HRS

2.12
test for trend
ref

1.05

3-5 HRS

1.26

5+ HRS

1.68

STAGE IV
<1 HR
1-3 HRS

test for trend
ref

cOR**

95% CI

adjusted
ref

3-5 HRS

STAGE III
<1 HR
1-3 HRS

p-value

1.58

3-5 HRS

3.23

5+ HRS

3.78
test for trend
Test of
interaction with
HIV

0.571.51
1.052.99
1.143.92

0.752

0.661.67
0.742.12
0.913.12

0.847

0.733.44
1.496.99
1.589.03

0.246

ref

pvalue

0.93

0.54-1.62

0.805

0.031

2.00.

1.14-3.52

0.015

0.017

2.18

1.10-4.31

0.025

0.002

test for trend
ref

0.002
1.07

0.62-1.86

0.804

0.396

1.51

0.84-2.71

0.165

0.099

1.72

0.86-3.46

0.127

0.076

test for trend
ref

0.056
1.33

0.55-3.25

0.528

0.003

2.97

1.28-6.90

0.011

0.003

4.26

1.61-11.30

0.004

<0.001
0.075

* conditional odds ratio

test for trend
Test of
interaction with
HIV

<0.001
0.155

** conditional odds ratios, adjusted for HIV status, age, marital status, report of abnormal vaginal bleeding, report of
ever screen, visit with a natural healer, urban vs. rural residence
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Figure 4. 3. Proportion of cervical cancer cases by HIV status across travel times

Table 4. 4. Logistic regression for travel time and HIV status
Travel time

HIV negative

HIV positive

N=282

N=660

p-value

aOR*

<0.001

ref

95% CI

<1 HR

84 (29.8%)

217 (32.9%)

1-3 HRS

97 (34.4%)

144 (21.8%)

0.64

0.39-1.04

0.073

3-5 HRS

67 (23.8%)

174 (26.4%)

1.33

0.80-2.23

0.271

5+ HRS

34 (12.1%)

125 (18.9%)

2.03

1.10-3.75

0.024

test for trend

p-value

0.002

* adjusted for stage at diagnosis, age, marital status, report of abnormal vaginal bleeding, report of ever screen, visit
with a natural healer
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Chapter 5. Summary and future directions
5.1. Summary

In summary, this dissertation titled: “Identifying demographic, clinical, and geographic
features of cervical cancer patients presenting to a multidisciplinary tumor (MDT) clinic in
Gaborone, Botswana”, offers insight and epidemiologic data that can be used to guide
future interventions and research to maximize the impact of implementing programs and
policies aimed at reducing the growing cervical cancer burden in Botswana.

Our first study examining demographic and clinical factors associated with late-stage
disease at presentation to the MDT clinic shows that prior cervical cancer screening is
associated with decreased odds of having late-stage cervical cancer at diagnosis,
whereas experiencing abnormal vaginal bleeding and having never been married are
associated with an increased odds of having late-stage cervical cancer at diagnosis.
Additionally, rural women who consulted a traditional healer have increased odds of
late-stage disease at diagnosis compared to rural women who have never consulted a
traditional healer.

We also found that living with HIV was not associated with having late-stage cervical
cancer at diagnosis, but when comparing WLWH and women without HIV in our cohort,
the WLWH were younger, were more likely to have undergone cervical cancer
screening, more often lived in urban areas, and were more likely to be married or to
have been married than women without HIV. Additionally, associations with late-stage
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cervical cancer at diagnosis differed between WLWH versus women without HIV.
Increasing age is significantly associated with late-stage cervical cancer at diagnosis in
women without HIV, but not in WLWH. WLWH with a history of cervical cancer screening
have lower odds of presenting with late-stage cervical cancer at diagnosis; however
cervical cancer screening is not significantly associated with late-stage cervical cancer at
diagnosis in women without HIV.

Our second study reveals non-random geographic patterns of patients with cervical
cancer throughout Botswana presenting to the MDT clinic in Gaborone. We identify
specific areas of the country with disproportionately high and low presentation rates,
indicating that areas with low presentation rates may have poor access to the one
comprehensive care MDT clinic in Botswana, and areas with high presentation rates
may have better access to the MDT clinic. Patients living in sub-districts with low
presentation rates are more likely to present with abnormal vaginal bleeding, and
patients living in sub-districts with high presentation rates are more likely to be HIV
negative and more likely to present with late stage disease.

Our results also generate novel hypothesis regarding community and individual level
factors that could be limiting access to health care for areas with low presentation rates,
such as travel-distance as a potential barrier to accessing cervical cancer care. We also
identify additional potential areas for interventions to mitigate the cervical cancer burden
at the individual level, including increasing efforts for women without HIV to assess and
improve knowledge related to cervical cancer and cervical cancer screening. Future
efforts should increase awareness campaigns and cervical cancer screening efforts to
include women without HIV. Additionally, early cervical cancer detection efforts should
86

also emphasize cancer symptom awareness and education about the steps women
should take if they experience these symptoms.

Our third study delineates the travel time for cervical cancer patients traveling from their
village of residence to the comprehensive MDT cancer clinic at PMH in Gaborone. The
average travel time was almost 3 hours and more than 200 km to the MDT clinic. We
note that patients have an increased odds of presenting with later stage disease with
increasing travel time to the MDT clinic. We also find that the rates of patients
presenting to the MDT clinic differ according travel times, with the highest presentation
rate for patients traveling 1-3 hours to the MDT clinic and lowest for patients traveling
more than five hours, thus our results indicate that not all women who develop cervical
cancer are presenting equally for staging and care. We also show that an association
with travel time and a patient’s HIV status. Patients with greater travel time to the MDT
clinic are more likely to be living with HIV, suggesting that HIV status may increase the
likelihood of presentation for cervical cancer care for women living at further distances.

In conclusion, increasing education and awareness among women, both women living
with and without HIV, and among providers, including traditional healers, about the
benefits of cervical cancer screening and about the importance of seeking prompt
medical care for abnormal vaginal bleeding, while also developing support systems for
unmarried women, may help reduce cervical cancer morbidity and mortality in Botswana.
Moreover, focusing future interventions on education, screening, and referral
infrastructure for cervical cancer in areas of Botswana where fewer women are
presenting for cervical cancer care, may increase the impact of programs and decrease
the cervical cancer burden. Lastly, identifying the need to investigate barriers to
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accessing advanced cancer care including the travel burden, cervical cancer awareness,
knowledge, and resources to ensure equitable access to appropriate treatment for all
women in Botswana, both WLWH and without, is needed to improve cervical cancer
outcomes. Our study shows cervical cancer as a burden in Botswana, and highlights
important risk factors, barriers to access, and areas for improved intervention.
Importantly, reliable resources, such as an up-to-date population based cancer registry,
are also needed to capture the true epidemiology of cervical cancer and for the future, to
be able to truly understand quantify the morbidity and mortality of cervical cancer so as
to understand and measure the impact of future interventions aimed at alleviating the
cancer burden.
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5.2. Future directions

Botswana carries a heavy burden of cervical cancer, access to adequate treatment is
essential to reduce disease and save lives. Improving equitable access to cervical
cancer treatment for women living in sub-districts with lower rates of cervical cancer
patients presenting for care should be prioritized to help reduce the morbidity and
mortality of cervical cancer. Future efforts to include women without HIV and women
who have not been married in cervical cancer screening efforts could result in the earlier
detection of cervical cancer in these groups. Future early cervical cancer detection
efforts should emphasize cancer symptom awareness and early detection through
cervical cancer screening, and should also include traditional healers in the cancer care
continuum.

Identifying community and individual level factors associated with access to
comprehensive cervical cancer care gives national health programs insight when
developing strategies that target areas and populations being underserved by health
facilities. These strategies will be key in preventing and controlling the emerging
cervical cancer burden in Botswana. Our results highlight patient level factors
associated with late-stage cervical at diagnosis and indicate potential areas for
intervention to mitigate the cervical cancer burden in Botswana. Our findings show that
cervical cancer screening for women in Botswana is associated with the early
detection of cervical cancer, particularly in women with HIV. Future efforts to include
women without HIV and women who have not been married in cervical cancer
screening efforts could result in the earlier detection of cervical cancer in these groups.
Future early cervical cancer detection efforts should emphasize cancer symptom
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awareness and early detection through cervical cancer screening, and should also
include traditional healers in the cancer care continuum.

Next steps for this work could include working with the appropriate stakeholders
(MOHW, UICC, etc) to prioritize resources to ensure more accurate estimates of cervical
cancer rates for the Botswana national cancer registry. This work highlights important
differences among women with and without HIV for cervical cancer screening, and that
not all women, specifically women without HIV, may not be presenting for cervical
cancer treatment because of the overall focus on implementing screening and testing for
high-risk WLWH. Currently, the health system may fail to recognize the need to
educate, screen and treat lower-risk women for cervical cancer and future work should
focus on including lower-risk women in cervical cancer prevention and screening efforts.

Next steps for a research study would be to identify additional barriers for access to
treatment. One could use a mixed methods study to identify health facilities in 2-3
different areas throughout Botswana (ex: one in Botswana, one 3 hours away and one 5
hours away) and investigate knowledge and understanding (availability and
acceptability) regarding cervical cancer and screening for patients and health care
providers, and evaluate structural and health systems to determine where interventions
make the most impact with a focus on ensuring equitable access to care for WLWH and
without.
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APPENDIX

A.1. Alternative methods for Chapter 3
A.1.1. Study participants and covariates

Study participants, patient demographic and clinical factors were all the same as that
main analysis. However, for more granular data, the GIS unit of analysis included 519
villages as defined by administrative boundaries for Botswana (8). Community level
variables for sub-districts included HIV prevalence, population density, and travel
distance to Gaborone were still based on sub-district of analysis as noted in 3.3.2.

A.1.2. Covariates

A.1.3. Geocoding Methods

To detect areas in Botswana with disproportionately high or low rates of cervical cancer
patients presenting for treatment, we defined our geographic unit of analysis as village of
residence in Botswana. We used an available shapefile from the USCB (8) to define the
administrative boundaries for 519 villages throughout the country. We abstracted each
patient’s residential village from the questionnaire and geocoded each patient to one of
USCB’s identified 519 villages (8). We aggregated cervical cancer patients per village.
The denominator for each sub-district consisted of the total female population projection
for patients 20 years and older from January 2015 to March 2020(8). We then calculated
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the age-standardized cervical cancer rates per 100,000 women for each sub-village.
Rates by village were visually inspected using choropleth maps for geographic variation.

A.1.4. Geographic Analysis

To statistically assess geographic correlation of cervical cancer patients both globally
and locally, we employed the Global Moran’s I and the Anselin local index of spatial
autocorrelation statistics, respectively (29, 30). We conducted a Global Moran’s I test to
assess if cervical cancer rates across the country were clustered, dispersed, or random.
The null hypothesis assumed that cervical cancer distribution was random across
Botswana. The cervical cancer rates of each village were correlated with the mean rate
of neighboring sub-districts. We defined neighbors using queen’s contiguity matrix (31)
and conducted permutation tests with 999 simulations for significance. A significant
Moran’s I test indicated a non-random geographic distribution and therefore spatial
autocorrelation would exist. A positive spatial autocorrelation result indicated clustering,
describing sub-districts with similar rates within close geographic proximity to each other.
Negative spatial autocorrelation revealed dispersion, noting sub-districts with dissimilar
rates were closer in geographical proximity in a manner that was not random.

Moran’s I analysis is limited in that it does not detect local patterns of spatial association
(29). To investigate local patterns of cervical cancer referral rates for each village we
employed the local index of spatial autocorrelation (30). This tool determined for each
individual (target) village if cervical cancer rates were uniformly similar or
disproportionately high or low relative the mean rate of that village’s neighbors, once
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again defined by Queen’s contiguity matrix (31). Permutation tests with 999 simulations
were conducted and statistically significant clusters (similar rates) or outliers (dissimilar
rates) were identified with 95% confidence intervals. A significant result revealed one of
four possible categories for each village, two types of clusters or two types of outliers. A
high-high (HH) cluster indicated target villages with high rates were surrounded by
neighboring villages with high rates, and conversely low-low (LL) clusters identified
target villages with low rates surrounded by neighboring villages with low rates. High-low
(HL) or low-high (LH) outliers indicated an inverse relationship between the target village
rates and the mean of their neighbor’s rates.

A.1.5. Statistical Analysis

Simple ordinary least squares (OLS) regression investigated the relationship of agestandardized rates across the country with village level community factors. If Moran’s I
identified any form of autocorrelation, we accounted for non-independence of rates in
our multivariable OLS regression mode using a spatial weights matrix(32) to investigate
associations with village level variables (HIV prevalence, population density, and travel
distance).

Lastly, we aimed to identify individual level characteristics that were associated with
patients living in an identified HH or LL villages. We investigated clinical and
demographic characteristics of cervical cancer patients living in an identified LL village
compared to patients not living in a LL village and also for patients living in an identified
HH village compared to patients not living in a HH village. Univariate individual level
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differences were assessed using student t-tests and chi-squared tests. Additionally,
multivariable logistic regression models determined the magnitude of associations for
patients living in identified LL or HH villages versus patients not living in these villages,
while adjusting for multiple demographic and clinical characteristics. Adjusted odds
ratios and 95% confidence intervals with a cut off off-value 0.05 determined significant
associations. We performed geospatial analysis in ArcGIS version 10.6.1 (Esri,
Redlands, CA), and Geo-da, and conducted all Statistical analysis in STATA 16.1.
A.2. Results
We manually matched 1006 of 1033 (97.5%) cervical cancer cases to villages identified
in the USCB database. Village match reviewed by Botswana Team. 1006 women
included in the analysis, observed rate was generated for each village. Underlying
population for women >20 years was per year was approximately 698,905, with an
observed rate of 14.4 per 10,000 women over the study period. Globocan estimated
374 incident cervical cancer cases in 2020, using the same underlying population, this
gave an expected rate of 30.2 per 10,000 women, giving an overall rate ratio of 47.7%.
We identified a non-random, clustered distribution of CC rates across the 519 villages in
Botswana as indicted by Global Moran’s I (p=0.010, Figure A.1), the LISA statistic
showed HH, HL, LL, and LH clusters (Figures A.2). Figure A.3 visually depicts the
distribution of cervical cancer rates throughout Botswana by village.
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Figure A. 1. Moran’s I results for clustering of cervical cancer rates throughout Botswana
by village
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Figure A. 2. Local Index of Spatial Autocorrelation by Village

LH

HH
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LL
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Figure A. 3.Distribution of cervical cancer rates throughout Botswana by village
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